Markers for distinguishing benign and malignant pulmonary nodules and their uses
Through peripheral blood gene marker screening and building a logistic regression model, the problem of screening benign and malignant lung micronuclear nodules is solved, the accuracy and specificity of early diagnosis is improved, and it is suitable for lung cancer screening in large-scale populations.
Patent Information
- Application Number
- CN202010368425.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-04-30
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2040-04-30
AI Technical Summary
The prior art is difficult to accurately identify the benign and malignant nature of pulmonary micronuclei, especially when the nodule size is less than 10 mm, resulting in difficulty in early diagnosis and insufficient specificity and sensitivity of imaging examinations and serum marker detection.
A peripheral blood gene marker was provided, and a logistic regression model was constructed by screening out the expression differences of genes such as CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A. Used to identify the benign and malignant nature of tiny lung nodules.
Accurate benign and malignant identification of micro-pulmonary nodules in the lungs is achieved, the sensitivity and specificity of early diagnosis is improved, false positive results are reduced, and ultra-early lung cancer screening is suitable for large-scale populations.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of molecular biology, and relates to the identification of benign and malignant pulmonary nodules, and specifically to markers and uses thereof for the identification of benign and malignant pulmonary micronodules. Background Art
[0002] Lung cancer is the leading cause of cancer death in my country's urban population. According to the 2011 Statistical Yearbook of the Ministry of Health, the mortality rate of lung cancer in my country in 2010 was 46.46 per 100,000 people, ranking first among malignant tumor mortality rates. The prognosis of lung cancer is closely related to the clinical stage at the time of diagnosis. Among them, the treatment effect of ultra-early stage Ia peripheral in situ lung cancer is the best, with a 5-year survival rate of up to 90% after surgery, while the overall 5-year survival rate of patients in stages II-IV drops from 34% to less than 5%. Therefore, the key to improving the cure rate of lung cancer and reducing the mortality rate is early detection.
[0003] Currently, the use of high-resolution imaging examination methods such as low-dose spiral CT (LDCT) to examine high-risk groups is a major means of early screening for lung cancer. LDCT has a high sensitivity. In large-scale early screening for lung cancer, about 20-30% of the subjects will be found to have micro-nodules (micro-nodules, nodules less than 10mm in size), but only 3.8% of them are malignant. At present, it is very difficult to judge the benign or malignant nature of micro-nodules in the clinic. This is mainly because the size of micro-nodules is less than 10mm, making it difficult to perform biopsy and pathological examinations through fine needle puncture. Even if PET-CT examinations are performed, the diagnostic value of the results obtained is very limited.
[0004] Blood is the largest tissue organ in the human body, and blood cells are one of the few cell types that can exchange information with almost all tissue cells. If tissues and organs in the body are damaged, inflamed, or have malignant diseases such as tumors, a series of specific changes will occur in the microenvironment around the diseased tissue cells. When blood flows through various tissues and organs, the microenvironment of the diseased tissue cells exchanges information with blood cells, and blood cells will directly or indirectly respond to these changes, undergo corresponding gene expression changes, and participate in the information transmission and exchange of various systems in the body such as the immune system. This gene expression change of blood cells occurs long before the body produces obvious signs and changes, and includes some disease-specific gene expression changes. Therefore, by closely monitoring the expression spectrum of blood cell genes, molecular information of early malignant diseases such as tumors in the body can be sensitively captured, and disease-specific gene expression signals (markers) can be screened out, providing reliable evidence for early detection and monitoring of the disease. Moreover, as a simple and non-invasive examination method, peripheral blood gene expression detection is easy for the examinees to accept and has high compliance, and has great application value for early screening / diagnosis of malignant tumors.
[0005] Serum tumor marker tests related to lung cancer, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC-Ag), cytokeratin 19 fragment, etc., have certain reference value for auxiliary diagnosis of advanced lung cancer, but have little diagnostic value for stage Ia lung cancer. In addition, serum protein markers have poor specificity for lung cancer detection. Other benign lesions such as pneumonia can also cause abnormal protein marker concentrations, leading to false positive test results. Therefore, in order to accurately distinguish between benign and malignant micronodules and detect ultra-early micronodule lung cancer as early as possible, the art needs a blood test technology and product that can accurately distinguish between benign and malignant micronodules. Summary of the invention
[0006] In view of the lack of biomarkers for accurately distinguishing benign and malignant pulmonary nodules, especially micronodules, in the prior art, the present invention provides a peripheral blood gene marker suitable for distinguishing benign and malignant pulmonary nodules. The marker has good sensitivity and specificity for distinguishing benign and malignant pulmonary nodules, and can accurately distinguish malignant nodules, which is of great significance for timely diagnosis, improving prognosis, and reducing mortality. Using the marker of the present invention, only 2 ml of peripheral venous blood needs to be collected for detection, and the detection process is simple, which is particularly suitable for ultra-early lung cancer screening for large-scale populations in conjunction with imaging examinations such as CT.
[0007] The present invention also provides a method for screening the above markers, and the markers obtained by this method have good sensitivity and specificity for lung nodules.
[0008] The present invention also provides a model for identifying micro-nodules in the lungs and a method for constructing the model.
[0009] Therefore, the present invention provides an isolated nucleic acid molecule, which is a lung nodule marker, wherein the nucleic acid molecule is 13-15000 bp in length, and the nucleic acid molecule has a DNA sequence selected from one, any multiple or all of the following, or a variant thereof having at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 99% identity, or a corresponding RNA sequence of the DNA sequence or variant: (1) the coding sequence of CEACAM4 or a fragment thereof matching SEQ ID NO: 43, or a complementary sequence thereof, (2) the coding sequence of S100A9 or a fragment thereof matching SEQ ID NO: 44, or a complementary sequence thereof, (3) the coding sequence of FCGR1A or a fragment thereof matching SEQ ID NO: 45, or a complementary sequence thereof, (4) the coding sequence of ROGDI or a fragment thereof matching SEQ ID NO: 46, or a complementary sequence thereof, (5) the coding sequence of ZNF266 or a fragment thereof matching SEQ ID NO: 47, or a complementary sequence thereof, (6) the coding sequence of TNFSF10 or a fragment thereof matching SEQ ID NO: NO:48, or their complementary sequences, (7) the coding sequence of MORF or a fragment thereof matching SEQ ID NO:49, or their complementary sequences, (8) the coding sequence of MCEMP1 or a fragment thereof matching SEQ ID NO:50, or their complementary sequences, (9) the coding sequence of TRAF5 or a fragment thereof matching SEQ ID NO:51, or their complementary sequences, (10) the coding sequence of SLC38A1 or a fragment thereof matching SEQ ID NO:52, or their complementary sequences, (11) the coding sequence of TARBP1 or a fragment thereof matching SEQ ID NO:53, or their complementary sequences, (12) the coding sequence of SMA4 or a fragment thereof matching SEQ ID NO:54, or their complementary sequences, (13) the coding sequence of HNRNPD or a fragment thereof matching SEQ ID NO:55, or their complementary sequences, and (14) the coding sequence of SMC1A or a fragment thereof matching SEQ ID NO:56, or their complementary sequences.
[0010] In one or more embodiments, the nucleic acid molecule is DNA or RNA.
[0011] In one or more embodiments, the length of the nucleic acid molecule is 13-50 bp, 13-45 bp, 13-40 bp, 13-35 bp, 13-31 bp.
[0012] In one or more embodiments, the length of the nucleic acid molecule is 13-14000 bp, 13-13000 bp, 13-12000 bp, 13-11000 bp, 13-10000 bp, 13-9710 bp.
[0013] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule.
[0014] In one or more embodiments, the pulmonary nodule is a pulmonary nodule having a diameter less than 10 mm.
[0015] In one or more embodiments, the coding sequence of CEACAM4 is as shown in SEQ ID NO:1.
[0016] In one or more embodiments, the coding sequence of S100A9 is as shown in SEQ ID NO:2.
[0017] In one or more embodiments, the coding sequence of FCGR1A is shown in SEQ ID NO:3.
[0018] In one or more embodiments, the coding sequence of ROGDI is shown in SEQ ID NO:4.
[0019] In one or more embodiments, the coding sequence of ZNF266 is shown in SEQ ID NO:5.
[0020] In one or more embodiments, the coding sequence of TNFSF10 is as shown in SEQ ID NO:6.
[0021] In one or more embodiments, the coding sequence of MORF is shown as SEQ ID NO:7.
[0022] In one or more embodiments, the coding sequence of MCEMP1 is shown as SEQ ID NO:8.
[0023] In one or more embodiments, the coding sequence of TRAF5 is shown in SEQ ID NO:9.
[0024] In one or more embodiments, the coding sequence of SLC38A1 is as shown in SEQ ID NO:10.
[0025] In one or more embodiments, the coding sequence of TARBP1 is shown in SEQ ID NO:11.
[0026] In one or more embodiments, the coding sequence of SMA4 is shown as SEQ ID NO:12.
[0027] In one or more embodiments, the coding sequence of HNRNPD is shown in SEQ ID NO:13.
[0028] In one or more embodiments, the coding sequence of SMC1A or is as shown in SEQ ID NO:14.
[0029] In one or more embodiments, the nucleic acid molecule has a DNA sequence selected from any of the following groups, or a variant thereof having at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 99% identity, or their corresponding RNA sequences:
[0030] a1: (3), (7), (8), (12) and (13),
[0031] a2: (1), (7), (8), (10) and (11),
[0032] a3: (1), (5), (7), (9) and (11),
[0033] a4: (3), (6), (7), (8), (11) and (12),
[0034] a5: (1), (3), (6), (8), (11) and (13),
[0035] a6: (6), (9), (10), (11), (12) and (14),
[0036] a7: (5), (6), (7), (8), (9), (10) and (13),
[0037] a8: (4), (8), (9), (10), (11), (13) and (14),
[0038] a9: (1), (3), (5), (7), (10), (12) and (13),
[0039] a10: (2), (4), (7), (9), (10), (12) and (13),
[0040] a11: (5), (6), (7), (8), (9), (10) and (13),
[0041] a12: (3), (7), (8), (9), (11), (12), (13) and (14),
[0042] a13: (1), (4), (7), (8), (9), (10), (12) and (13),
[0043] a14: (6), (7), (8), (9), (10), (11), (12) and (14),
[0044] a15: (1), (3), (4), (7), (9), (10), (12), (13) and (14),
[0045] a16: (1), (4), (5), (8), (9), (10), (12), (13) and (14),
[0046] a17: (2), (3), (8), (9), (10), (11), (12), (13) and (14),
[0047] a18: (3), (4), (6), (7), (8), (10), (11), (12), (13) and (14),
[0048] a19: (1), (2), (3), (4), (5), (9), (10), (11), (13) and (14),
[0049] a20: (1), (2), (4), (5), (6), (8), (9), (10), (11) and (14),
[0050] a21: (1), (2), (4), (5), (6), (7), (8), (11), (12), (13) and (14),
[0051] a22: (1), (2), (3), (6), (8), (9), (10), (11), (12), (13) and (14),
[0052] a23: (1), (2), (3), (4), (5), (6), (7), (8), (12), (13) and (14),
[0053] a24: (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14),
[0054] a25: (1), (2), (3), (4), (6), (7), (8), (9), (10), (11), (13) and (14),
[0055] a26: (1), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13),
[0056] a27: (1), (2), (3), (4), (5), (7), (8), (9), (10), (11), (12), (13) and (14),
[0057] a28: (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (12), (13) and (14),
[0058] a29: (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (13) and (14), or
[0059] a30: (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14).
[0060] In one or more embodiments, the nucleic acid molecule has a sequence as shown in SEQ ID NO: 1-14 or a corresponding RNA sequence thereof. In one or more embodiments, the nucleic acid molecule has a sequence as shown in SEQ ID NO: 43-56 or a corresponding RNA sequence thereof.
[0061] In one or more of the above embodiments, the DNA sequence includes the sense strand or antisense strand of genomic DNA.
[0062] In one or more of the above embodiments, the nucleic acid molecule is used as an internal standard or control for detecting the transcription level, translation level, content, or methylation of the corresponding DNA sequence or RNA sequence in a sample.
[0063] The second aspect of the present invention provides a reagent for detecting
[0064] (1) the transcription level, translation level, content or methylation of one or more of the nucleic acid molecules described in the first aspect of this invention; or
[0065] (2) The content or activity of the expression product of (1).
[0066] In one or more embodiments, the sample is from a mammal, preferably a human.
[0067] In one or more embodiments, the reagent is a reagent used in one or more of the following methods: PCR, DNA sequencing, RNA sequencing, DNA hybridization, RNA hybridization, Southern, Northern, Western, immunoprecipitation, ELISA, restriction endonuclease analysis, high-resolution melting curve method, mass spectrometry, preferably RT-qPCR, RNA sequencing or chip-based methods.
[0068] In one or more embodiments, the reagent is selected from one or more of the following: buffer, reverse transcriptase, polymerase, dNTP, primer, probe, restriction endonuclease, fluorescent dye, fluorescence quencher, fluorescent reporter, exonuclease, alkaline phosphatase, internal standard, control.
[0069] In one or more embodiments, the reagent is a primer. In one or more embodiments, the primer recognizes one or more of the nucleic acid molecules described in the first aspect of the present invention. In one or more embodiments, the primer can be a primer for genome sequencing, such as a full genome sequencing primer or a sequencing primer for a portion of a genome, or a primer for amplifying the nucleic acid molecules described herein. Preferably, the primer has a sequence shown in one or more or all of SEQ ID NOs: 15-42.
[0070] In one or more embodiments, the reagent is a nucleic acid probe. In one or more embodiments, the probe hybridizes with the nucleic acid molecule described in the first aspect of this invention under stringent conditions. Preferably, the two ends of the sequence of the probe respectively contain a fluorescent reporter group and a quencher group. Preferably, the nucleic acid probe has a sequence shown in one or more or all of SEQ ID NOs: 43-56 or its corresponding RNA sequence.
[0071] The present invention also provides a composition comprising the reagent described in the second aspect of this invention. Preferably, the composition comprises the primer and / or nucleic acid probe described in the second aspect of this invention.
[0072] The present invention also provides a gene chip comprising the nucleic acid probes and / or polypeptide probes described herein.
[0073] The present invention also provides a kit, comprising the reagent described in the second aspect of this article and the optional nucleic acid molecule described in the first aspect of this article. The kit is used to distinguish benign and malignant pulmonary nodules. In one or more embodiments, the pulmonary nodules are pulmonary micronodules. In one or more embodiments, the pulmonary nodules are pulmonary nodules with a diameter of less than 10 mm.
[0074] In one or more embodiments, the kit further comprises primers and / or probes for detecting a reference sequence. Preferably, the reference sequence is a sequence of GAPDH or a fragment thereof. Preferably, the primers for the reference sequence have the sequences shown in SEQ ID NO:57 and / or 58; the probes for the reference sequence have the sequences shown in SEQ ID NO:59 or their corresponding RNA sequences.
[0075] In one or more embodiments, the kit further comprises a fluorescent probe that specifically binds to the PCR amplified fragment or a dye that non-specifically binds to the fragment.
[0076] The third aspect of the present invention also provides the use of one or more or all of the following genes or their DNA or RNA sequences in the animal genome in the preparation of reagents and / or kits for distinguishing benign and malignant lung nodules: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A.
[0077] In one or more embodiments, the reagent detects (1) the transcription level, translation level, content or methylation of the gene in the sample; or (2) the content or activity of the expression product of (1); preferably, the reagent is a primer or a probe.
[0078] In one or more embodiments, the DNA or RNA sequence of the gene in the animal genome is as described in the nucleic acid molecule of the first aspect herein.
[0079] In one or more embodiments, the gene is selected from any of the following groups:
[0080] a1: FCGR1A, MCEMP1, MORF, SMA4 and HNRNPD,
[0081] a2: CEACAM4, MCEMP1, MORF, SLC38A1 and TARBP1,
[0082] a3: CEACAM4, TRAF5, MORF, ZNF266 and TARBP1,
[0083] a4: FCGR1A, MCEMP1, MORF, TARBP1, TNFSF10 and SMA4,
[0084] a5: CEACAM4, FCGR1A, MCEMP1, TARBP1, TNFSF10 and HNRNPD,
[0085] a6: SLC38A1, TARBP1, TNFSF10, TRAF5, SMA4 and SMC1A,
[0086] a7: HNRNPD, TNFSF10, SLC38A1, MCEMP1, ZNF266, TRAF5 and MORF,
[0087] a8: MCEMP1, ROGDI, SLC38A1, TARBP1, TRAF5, HNRNPD and SMC1A,
[0088] a9: CEACAM4, FCGR1A, MORF, SLC38A1, ZNF266, SMA4 and HNRNPD,
[0089] a10: MORF, ROGDI, S100A9, SLC38A1, TRAF5, SMA4 and HNRNPD,
[0090] a14: TRAF5, MCEMP1, MORF, SLC38A1, TNFSF10, ZNF266 and HNRNPD,
[0091] a12: FCGR1A, MCEMP1, MORF, TARBP1, TRAF5, SMA4, HNRNPD and SMC1A,
[0092] a13: CEACAM4, MCEMP1, MORF, ROGDI, SLC38A1, TRAF5, SMA4, and HNRNPD,
[0093] a14: MCEMP1, MORF, SLC38A1, TARBP1, TNFSF10, TRAF5, SMA4 and SMC1A,
[0094] a15: CEACAM4, FCGR1A, MORF, ROGDI, SLC38A1, TRAF5, SMA4, HNRNPD and SMC1A,
[0095] a16: CEACAM4, MCEMP1, ROGDI, SLC38A1, TRAF5, ZNF266, SMA4, HNRNPD, and SMC1A,
[0096] a17: FCGR1A, A, C, EMP1, S100A9, SLC38A1, TARBP1, TRAF5, SMA4, HNRNPD, and SMC1A,
[0097] a18: FCGR1A, MCEMP1, MORF, ROGDI, SLC38A1, TARBP1, TNFSF10, SMA4, HNRNPD and SMC1A,
[0098] a19: CEACAM4, FCGR1A, ROGDI, S100A9, SLC38A1, TARBP1, TRAF5, ZNF266, HNRNPD, and SMC1A,
[0099] a20: CEACAM4, MCEMP1, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, and SMC1A,
[0100] a21: CEACAM4, MCEMP1, MORF, ROGDI, S100A9, TARBP1, TNFSF10, ZNF266, SMA4, HNRNPD, and SMC1A,
[0101] a22: CEACAM4, FCGR1A, MCEMP1, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, SMA4, HNRNPD, and SMC1A,
[0102] a23: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, TNFSF10, ZNF266, SMA4, HNRNPD, and SMC1A,
[0103] a24: FCGR1A, MCEMP1, MORF, ROGDI, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD, and SMC1A,
[0104] a25: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, HNRNPD, and SMC1A,
[0105] a26: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4, and HNRNPD,
[0106] a27: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TRAF5, ZNF266, SMA4, HNRNPD, and SMC1A,
[0107] a28: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD, and SMC1A,
[0108] a29: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, HNRNPD, and SMC1A or
[0109] a30: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD and SMC1A.
[0110] In one or more embodiments, the animal is a mammal, preferably a human.
[0111] In one or more embodiments, the genome is human genome hg19.
[0112] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0113] The present invention also provides the use of the nucleic acid molecule described in any embodiment of the present invention in the preparation of a reagent and / or a kit for distinguishing benign or malignant pulmonary nodules.
[0114] The present invention also provides the use of the reagent described herein and optionally the nucleic acid molecule described herein in the preparation of a kit for distinguishing benign from malignant pulmonary nodules, wherein the reagent detects (1) the transcription level, translation level, content or methylation of one or more of the nucleic acid molecules described in the first aspect of the present invention in a sample; or (2) the content or activity of the expression product of (1).
[0115] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0116] In one or more embodiments of the use, the sample is from a mammal, preferably a human. In one or more embodiments, the sample is from a tissue, a cell or a body fluid, such as a non-tissue or blood. In one or more embodiments, the sample comprises plasma, serum or blood.
[0117] In one or more embodiments, the reagent is a reagent used in one or more of the following methods: PCR, DNA sequencing, RNA sequencing, DNA hybridization, RNA hybridization, Southern, Western, immunoprecipitation, ELISA, restriction endonuclease analysis, high resolution melting curve method, mass spectrometry, preferably RT-qPCR, RNA sequencing or chip-based methods.
[0118] In one or more embodiments, the reagent is selected from one or more of the following: buffer, polymerase, dNTP, primer, probe, restriction endonuclease, fluorescent dye, fluorescence quencher, fluorescent reporter, exonuclease, alkaline phosphatase, internal standard, control.
[0119] In one or more embodiments, the reagent is a primer. In one or more embodiments, the primer recognizes one or more of the nucleic acid molecules described in the first aspect of the present invention. In one or more embodiments, the primer can be a primer for genome sequencing, such as a full genome sequencing primer or a sequencing primer for a portion of a genome, or a PCR primer for amplifying the nucleic acid molecules described herein.
[0120] In one or more embodiments, the reagent is a nucleic acid probe. In one or more embodiments, the probe hybridizes with the nucleic acid molecule described in the first aspect of the present invention under stringent conditions. Preferably, the two ends of the sequence of the probe contain a fluorescent reporter group and a quencher group, respectively.
[0121] In one or more embodiments, the agent is a polypeptide probe. In one or more embodiments, the polypeptide probe specifically binds to the expression product of the nucleic acid molecule described in the first aspect of the present invention.
[0122] In one or more embodiments, the kit is a real-time quantitative PCR kit, an RNA sequencing kit, or a kit containing a gene chip.
[0123] In one or more embodiments, the real-time quantitative PCR kit comprises primers that specifically amplify one or more sequences shown in SEQ ID NOs: 1 to 14. Preferably, the primers have sequences shown in one or more or all of SEQ ID NOs: 15 to 42.
[0124] In one or more embodiments, the kit containing a gene chip comprises a nucleic acid probe that hybridizes under stringent conditions with one or more of the sequences shown in SEQ ID NOs: 1 to 14. Preferably, the nucleic acid probe has a sequence shown in one or more or all of SEQ ID NOs: 43 to 56 or its corresponding RNA sequence.
[0125] The present invention also provides a method for distinguishing benign and malignant pulmonary nodules, comprising:
[0126] (1) obtaining expression detection results of one or more or all of the following genes in the sample: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A,
[0127] (2) obtaining a score by constructing a model using the expression detection results,
[0128] (3) Differentiate between benign and malignant pulmonary nodules based on the scores.
[0129] In one or more embodiments, the expression detection result is the RNA content, expression product content, or RT-PCR result of the gene.
[0130] In one or more embodiments, the expression detection result is the detection result of the nucleic acid molecule or its expression product described in the first aspect of this article, preferably the RNA content, the content of the nucleic acid molecule expression product, or the RT-PCR result of the nucleic acid molecule.
[0131] In one or more embodiments, step (1) includes testing the sample to obtain the expression detection result.
[0132] In one or more embodiments, the gene of step (1) is selected from any one of the groups a1-a30 described in the third aspect herein.
[0133] In one or more embodiments, the sample is a lung tissue sample or a lung nodule sample.
[0134] In one or more embodiments, the sample is blood, serum or plasma. Preferably, the sample is peripheral blood, serum or plasma.
[0135] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0136] In one or more embodiments, the model in step (2) is a logistic regression model.
[0137] In one or more embodiments, the model is as follows:
[0138]
[0139] therefore,
[0140]
[0141] Among them, ΔCt1 to ΔCt nare the difference between the quantitative PCR cycle number Ct value of the nth nucleic acid molecule and the reference sequence, b0 to b n are the corresponding logistic regression model parameters respectively; σ(z) or P is the score.
[0142] In one or more embodiments, step (3) includes: when the score meets the threshold, the pulmonary nodule is identified as benign or malignant. In one or more embodiments, the pulmonary nodule is identified as malignant when the score is greater than or equal to the threshold, and the pulmonary nodule is identified as benign when the score is less than the threshold.
[0143] The present invention further provides a device, characterized in that the device comprises a memory, a processor, and a computer program stored in the memory and executable on the processor, characterized in that when the processor executes the program, the following steps are implemented:
[0144] (1) obtaining expression detection results of one or more or all of the following genes in the sample: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A,
[0145] (2) obtaining a score by constructing a model using the expression detection results,
[0146] (3) Differentiate between benign and malignant pulmonary nodules based on the scores.
[0147] In one or more embodiments, the expression detection result is the RNA content, expression product content, or RT-PCR result of the gene.
[0148] In one or more embodiments, the expression detection result is the detection result of the nucleic acid molecule or its expression product described in the first aspect of this article, preferably the RNA content, the content of the nucleic acid molecule expression product, or the RT-PCR result of the nucleic acid molecule.
[0149] In one or more embodiments, step (1) comprises testing the sample to obtain the test result.
[0150] In one or more embodiments, the sample is a lung tissue sample or a lung nodule sample.
[0151] In one or more embodiments, the sample is blood, serum or plasma. Preferably, the sample is peripheral blood, serum or plasma.
[0152] In one or more embodiments, the model in step (2) is a logistic regression model.
[0153] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0154] In one or more embodiments, the gene of step (1) is selected from any one of the groups a1-a30 described in the third aspect herein.
[0155] The present invention further provides a computer-readable storage medium, characterized in that a computer program is stored on the storage medium, and when the computer program is executed by a processor, the following steps are implemented:
[0156] (1) obtaining expression detection results of one or more or all of the following genes in the sample: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A,
[0157] (2) obtaining a score by constructing a model using the expression detection results,
[0158] (3) Differentiate between benign and malignant pulmonary nodules based on the scores.
[0159] In one or more embodiments, the expression detection result is the RNA content, expression product content, or RT-PCR result of the gene.
[0160] In one or more embodiments, the expression detection result is the detection result of the nucleic acid molecule or its expression product described in the first aspect of this article, preferably the RNA content, the content of the nucleic acid molecule expression product, or the RT-PCR result of the nucleic acid molecule.
[0161] In one or more embodiments, step (1) comprises testing the sample to obtain the test result.
[0162] In one or more embodiments, the sample is a lung tissue sample or a lung nodule sample.
[0163] In one or more embodiments, the sample is blood, serum or plasma. Preferably, the sample is peripheral blood, serum or plasma.
[0164] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0165] In one or more embodiments, the model in step (2) is a logistic regression model.
[0166] In one or more embodiments, the gene of step (1) is selected from any one of the groups a1-a30 described in the third aspect herein.
[0167] The present invention also provides a system for distinguishing benign and malignant pulmonary nodules, which is characterized by comprising:
[0168] A collection device for obtaining expression detection results of one or more or all of the following genes in a sample: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A, preferably the genes are selected from any one of the groups a1-a30 described in the third aspect of this invention,
[0169] A data processing device, used to obtain a score by constructing a model using the detection result,
[0170] The determination device is used to distinguish benign or malignant pulmonary nodules based on the scores.
[0171] In one or more embodiments, the collection device is a device for inputting the test results.
[0172] In one or more embodiments, the collection device is a detection device. The detection device includes a sample processing device and a measurement device.
[0173] In one or more embodiments, the expression detection result is the RNA content, expression product content, or RT-PCR result of the gene.
[0174] In one or more embodiments, the expression detection result is the detection result of the nucleic acid molecule or its expression product described in the first aspect of this article, preferably the RNA content, the content of the nucleic acid molecule expression product, or the RT-PCR result of the nucleic acid molecule.
[0175] In one or more embodiments, step (1) comprises testing the sample to obtain the test result.
[0176] In one or more embodiments, the sample is a lung tissue sample or a lung nodule sample.
[0177] In one or more embodiments, the sample is blood, serum or plasma. Preferably, the sample is peripheral blood, serum or plasma.
[0178] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0179] In one or more embodiments, the model in step (2) is a logistic regression model.
[0180] The present invention also provides a method for screening genes for distinguishing benign and malignant pulmonary nodules, comprising:
[0181] (1) Obtaining gene expression data of malignant pulmonary nodule samples and benign pulmonary nodule samples,
[0182] (2) Select genes expressed in all samples for T-test analysis.
[0183] (3) Compare the gene expression differences between malignant pulmonary nodule samples and benign pulmonary nodule samples, and select genes with a statistical P value less than 0.05 and a gene expression change of more than 1.1 times as candidate genes.
[0184] Optional (4) sorting the gene expression data according to the correlation between the benign and malignant nature of the sample, and selecting genes with a high correlation with malignant pulmonary nodules as candidate genes,
[0185] (5) Using logistic regression statistical analysis to screen candidate genes,
[0186] (6) screening the candidate genes obtained in step (5) for genes with consistent expression changes by real-time fluorescence quantitative PCR and gene chip methods,
[0187] Optionally (7) construct a model using logistic regression statistical analysis to evaluate the role of the genes obtained in step (5) in distinguishing benign and malignant lung nodules.
[0188] In one or more embodiments, the gene expression data is the content of RNA or the content of nucleic acid molecule expression products.
[0189] In one or more embodiments, the gene for distinguishing benign and malignant pulmonary nodules is selected from one or more or all of the following: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A. In one or more embodiments, the gene for distinguishing benign and malignant pulmonary nodules is selected from any one of the groups a1-a30 described in the third aspect of this invention.
[0190] In one or more embodiments, the correlation in step (4) is expressed as a Pearson correlation coefficient.
[0191] In one or more embodiments, step (5) includes constructing a model for the candidate genes using a logistic regression statistical analysis method, and screening the candidate genes according to the AUC size.
[0192] In one or more embodiments, the model of steps (5) and / or (7) is as follows
[0193]
[0194] Among them, ΔCt1 to ΔCt n are the differences in the quantitative PCR cycle numbers Ct values of n markers and the reference sequence, b0 to b n are the corresponding logistic regression model parameters respectively; σ(z) or P is the score.
[0195] In one or more embodiments, the sample is a lung tissue sample or a lung nodule sample.
[0196] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0197] In one or more embodiments, the sample is blood, serum or plasma. Preferably, the sample is peripheral blood, serum or plasma.
[0198] The present invention also provides a method for constructing a model for distinguishing benign and malignant pulmonary nodules, comprising:
[0199] (1) obtaining expression detection results of one or more or all of the following genes in the sample: CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A,
[0200] (2) Calculate the ROC curve and area under the curve for each candidate gene combination, and establish a model using logistic regression statistical analysis method.
[0201] In one or more embodiments, the pulmonary nodule is a pulmonary micronodule. In one or more embodiments, the pulmonary nodule is a pulmonary nodule with a diameter less than 10 mm.
[0202] In one or more embodiments, the detection result is the content of RNA, the content of the expression product of the nucleic acid molecule, or the difference in the quantitative PCR cycle number Ct value between the nucleic acid molecule and the internal reference gene.
[0203] In one or more embodiments, step (1) comprises testing the sample to obtain the test result.
[0204] In one or more embodiments, the model is as follows
[0205]
[0206] Among them, ΔCt1 to ΔCt n are the differences in the quantitative PCR cycle numbers Ct values of n markers and the reference sequence, b0 to b n are the corresponding logistic regression model parameters respectively; σ(z) or P is the score.
[0207] In one or more embodiments, the gene of step (1) is selected from any one of the groups a1-a30 described in the third aspect herein.
[0208] The present invention also provides a model for distinguishing benign and malignant pulmonary nodules, which is constructed according to the above method for constructing a model for distinguishing benign and malignant pulmonary nodules. In one or more embodiments, the pulmonary nodules are micropulmonary nodules. In one or more embodiments, the pulmonary nodules are pulmonary nodules with a diameter of less than 10 mm.
[0209] In one or more embodiments, the model is as follows
[0210]
[0211] Among them, ΔCt1 to ΔCt n are the differences in the quantitative PCR cycle numbers Ct values of n markers and the reference sequence, b0 to b n are the corresponding logistic regression model parameters respectively; σ(z) or P is the score. BRIEF DESCRIPTION OF THE DRAWINGS
[0212] Figure 1 The expression of different genes in benign and malignant samples is shown, with the gene as the horizontal axis and the RT-PCR expression value as the vertical axis.
[0213] Figure 2 : is the ROC curve of the exemplary embodiment, with the false positive rate (1-specificity) as the horizontal axis and the true positive rate (sensitivity) as the vertical axis. The closer the AUC is to 1, the better the diagnostic effect. DETAILED DESCRIPTION
[0214] After many attempts, the inventors finally determined that the expression differences of 14 genes can best show the differences between benign and malignant pulmonary nodules. These 14 genes are: CEACAM4 (SEQ ID NO: 1), S100A9 (SEQ ID NO: 2), FCGR1A (SEQ ID NO: 3), ROGDI (SEQ ID NO: 4), ZNF266 (SEQ ID NO: 5), TNFSF10 (SEQ ID NO: 6), MORF (SEQ ID NO: 7), MCEMP1 (SEQ ID NO: 8), TRAF5 (SEQ ID NO: 9), SLC38A1 (SEQ ID NO: 10), TARBP1 (SEQ ID NO: 11), SMA4 (SEQ ID NO: 12), HNRNPD (SEQ ID NO: 13) and SMC1A (SEQ ID NO: 14). In this article, the sequences shown and the sequence table are regarded as positive chains.
[0215] "Nodules" are a multi-system and multi-organ granulomatous disease of unknown etiology, often invading the lungs, bilateral hilar lymph nodes, eyes, skin and other organs. Pulmonary micronodules or small nodules are pulmonary nodules with a size of less than 10 mm. Pulmonary nodules can be malignant or benign, and malignant pulmonary nodules are also called lung cancer.
[0216] The "marker" described herein can be a nucleic acid molecule or its expression product. The nucleic acid molecule can be a nucleic acid molecule isolated from an animal, or can be an artificially synthesized nucleic acid molecule having an animal genome fragment sequence.
[0217] Herein, methods for detecting gene expression levels are well known in the art, such as PCR, DNA sequencing, RNA sequencing, DNA hybridization, RNA hybridization, Southern, Western, immunoprecipitation, ELISA, restriction endonuclease analysis, high-resolution melting curve method, mass spectrometry, preferably RT real-time quantitative PCR, RNA sequencing or chip-based methods.
[0218] Therefore, the present invention relates to reagents for detecting gene expression levels. The reagents used in the above-mentioned methods for detecting gene expression levels are well known in the art. Exemplarily, the reagents for detecting gene expression levels may include one or more of the following: buffer, polymerase, dNTP, primer, probe, restriction endonuclease, fluorescent dye, fluorescent quencher, fluorescent reporter, exonuclease, alkaline phosphatase, internal standard, control. In the detection method involving DNA amplification, the detection reagent includes a primer. The reagent for detecting gene expression levels can also be a polypeptide probe such as an antibody. The polypeptide probe specifically binds to the expression product of the nucleic acid molecule described herein, for example, the polypeptide probe is an antibody that specifically binds to the expression product of the nucleic acid molecule described in the first aspect of the present invention. The reagent for detecting gene expression levels can also be a nucleic acid probe. Generally, the 5' end of the sequence of the nucleic acid probe is labeled with a fluorescent reporter group, and the 3' end is labeled with a quenching group. The nucleic acid probe described herein can hybridize with the genomic sequence, coding sequence, RNA sequence or cDNA sequence of the gene described herein under stringent conditions. The stringent conditions for nucleic acid hybridization are known to those skilled in the art. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98% or 99% homologous to each other generally remain hybridized to each other. A non-limiting example of stringent hybridization conditions is hybridization at 65°C in a high salt buffer containing 6xSSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficolll, 0.02% BSA and 500 mg / ml denatured salmon sperm DNA, and optionally washed once or twice at 50°C in 0.2xSSC, 0.01% BSA.
[0219] In an exemplary embodiment, the present invention uses RT-qPCR to detect gene expression. The steps and required reagents of conventional RT-qPCR are known in the art. Generally, the steps of RT-qPCR include: reverse transcription, denaturation, annealing, and extension. The reagents used in RT-qPCR include: buffer, reverse transcriptase, primers, probes, dNTPs, DNA polymerase, and controls.
[0220] Herein, the sample is from a mammal, preferably a human. The sample may be from any organ (e.g., lung), tissue (e.g., epithelial tissue, connective tissue, muscle tissue, and neural tissue), cell (e.g., lung nodule cell), or body fluid (e.g., blood, plasma, serum, tissue fluid, urine). In an exemplary embodiment, the sample is peripheral blood.
[0221] The present invention also relates to a kit for identifying pulmonary nodules, comprising the reagents described herein, in particular the reagents described in the second aspect of this invention. The kit may also comprise the nucleic acid molecules described herein, in particular the nucleic acid molecules described in the first aspect as internal standards or positive controls. In addition to the reagents and nucleic acid molecules, the kit may also comprise other reagents required for detecting expression. Exemplarily, the kit may comprise one or more of the following: tools and / or reagents for collecting samples from a subject, tools and / or reagents suitable for long-term storage of samples and / or controls, tools and / or reagents for pre-treating samples and / or controls.
[0222] The "primer" described herein refers to a nucleic acid molecule with a specific nucleotide sequence that guides synthesis at the start of nucleotide polymerization. Primers are usually two artificially synthesized oligonucleotide sequences, one primer is complementary to a DNA template strand at one end of the target region, and the other primer is complementary to another DNA template strand at the other end of the target region, and its function is to serve as the starting point of nucleotide polymerization. Primers designed artificially in vitro are widely used in polymerase chain reaction (PCR), qPCR, sequencing, and probe synthesis. Typically, primers are designed to amplify products with a length of 50 to 150 bp, 60-140, 70-130, 80-120 bp. The primers contained in the reagents herein can be primers for genome sequencing, such as whole genome sequencing primers or sequencing primers for a certain region of the genome, or PCR primers for amplifying genes or their specific DNA regions or fragments. The art knows the design method of whole genome sequencing primers or PCR primers for a certain region or a certain site in the region.
[0223] The term "variant" or "mutant" herein refers to a polynucleotide that changes the nucleic acid sequence by inserting, deleting or replacing one or more nucleotides compared to a reference sequence while retaining its ability to hybridize with other nucleic acids. The mutant described in any embodiment herein includes a nucleotide sequence that has at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90%, preferably at least 95%, preferably at least 97% sequence identity with the reference sequence and retains the biological activity of the reference sequence. The sequence identity between two aligned sequences can be calculated using, for example, NCBI's BLASTn. Mutants also include nucleotide sequences that have one or more mutations (insertions, deletions or substitutions) in the reference sequence and nucleotide sequence while still retaining the biological activity of the reference sequence. The multiple mutations generally refer to within 1-10, such as 1-8, 1-5 or 1-3. The substitution may be a substitution between a purine nucleotide and a pyrimidine nucleotide, or between a purine nucleotide or between a pyrimidine nucleotide. The substitution is preferably a conservative substitution. For example, in the art, conservative substitutions with nucleotides with similar or similar properties generally do not change the stability and function of the polynucleotide. Conservative substitutions include, for example, the exchange of (A and G) between purine nucleotides and the exchange of (T or U and C) between pyrimidine nucleotides. Therefore, replacing one or several sites with residues from the same residue in the polynucleotide of the present invention will not substantially affect its activity.
[0224] In certain specific embodiments, the markers of the present invention are screened by the following method: 1) peripheral blood samples are collected from patients with malignant micronodules and benign micronodules. All patients with micronodules were confirmed to have nodules less than or equal to 10 mm in size by CT scan, and 2-3 ml of peripheral blood was collected from each sample; 2) Gene chip was used to obtain the peripheral blood gene expression spectrum data of the samples, and the expression spectrum data was normalized; 3) Genes with moderate expression (signal values between 100-10000) in all samples were selected for T-test analysis to compare the differences in peripheral blood gene expression between micronodule lung cancer and benign nodules, and genes with a statistical P value less than 0.05 and a gene expression fold change of more than 1.1 times were selected as candidate genes for subsequent analysis; 4) the correlation between the above candidate genes and micronodule lung cancer was analyzed, and the genes were ranked according to the correlation coefficient with micronodule lung cancer, and a group of gene cohorts with high correlation with micronodule lung cancer were selected (gene cohort I); in addition, the remaining The remaining genes were analyzed for correlation with the genes in cohort I, and another group of gene cohorts (gene cohort II) with high correlation with gene cohort I was selected; then the genes in gene cohort I and gene cohort II were paired in pairs to form a series of candidate gene combinations; 5) The logistic regression statistical analysis method was used to evaluate the discrimination effect of each candidate gene combination on micronodular lung cancer, and the receiver operating characteristic curve (ROC curve) and area under the curve value AUC of each candidate gene combination were calculated to screen out a series of gene combinations with good discrimination ability for micronodular lung cancer; 6) The screened series of gene combinations were verified by real-time fluorescence quantitative PCR method, and the genes with consistent expression changes in quantitative PCR and gene expression profile chip detection were retained as peripheral blood characteristic genes of micronodular lung cancer. The significance of the 14 lung cancer characteristic genes was shown in Figure 1 8) Use logistic regression statistical analysis to evaluate the diagnostic effect of any combination of the above 14 genes on micronodular lung cancer, calculate the ROC AUC of the gene combination, and establish the micronodular lung cancer discrimination model shown below:
[0225]
[0226] Among them, σ(z) or P is the risk value of developing micronodular lung cancer (malignant pulmonary nodules), that is, the score; ΔCt1 to ΔCt n are the differences in the quantitative PCR cycle numbers Ct values of n markers and the reference sequence, b0 to b n are the corresponding logistic regression model parameters respectively; z is the log likelihood ratio of logistic regression.
[0227] In one or more embodiments, when compared with the control sample, the expression level of the subject sample increases or decreases. The expression of the measured gene is mathematically analyzed to obtain a score. For the sample detected, when the score is greater than the threshold, the result is determined to be positive, i.e., a malignant nodule, otherwise it is negative, i.e., a benign nodule. The method of conventional mathematical analysis and the process of determining the threshold are known in the art, and an exemplary method is a mathematical model, such as a logistic regression model, a support vector machine model, and a random forest model. For example, for differentially expressed markers, a logistic regression model, a support vector machine model, or a random forest model is constructed for two groups of samples, and the accuracy, sensitivity and specificity of the test results and the area under the predictive characteristic curve (ROC) (AUC) of the model statistics are used to statistically test the test set sample prediction score.
[0228] Those skilled in the art are aware of conventional methods for constructing logistic regression models. An exemplary model is as follows:
[0229]
[0230]
[0231] In addition, the present invention also discloses a computer-readable storage medium storing a computer program, and the computer program stored on the storage medium executes the method for distinguishing benign and malignant pulmonary nodules described herein after running. The steps of the method or algorithm described in conjunction with the embodiments disclosed herein can be directly embodied in hardware, in a software module executed by a processor, or in a combination of the two. If implemented as a computer program product in software, each function can be stored on a computer-readable medium or transmitted by it as one or more instructions or codes. Computer-readable media include both computer storage media and communication media, including any medium that facilitates the transfer of computer programs from one place to another. The storage medium can be any available medium that can be accessed by a computer. As an example and not limitation, such a computer-readable medium may include RAM, ROM, EEPROM, CD-ROM or other optical disk storage, disk storage or other magnetic storage device, or any other medium that can be used to carry or store a desired program code in the form of an instruction or data structure and can be accessed by a computer. An exemplary storage medium is coupled to a processor so that the processor can read and write information from / to the storage medium. In an alternative, the storage medium can be integrated into the processor. The processor and the storage medium can reside in an ASIC. The ASIC may reside in a user terminal. In the alternative, the processor and the storage medium may reside as discrete components in a user terminal.
[0232] Example
[0233] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples. In the following examples, the experimental methods without specifying specific conditions are usually carried out according to the methods described in conventional conditions.
[0234] Example 1: Screening of peripheral blood characteristic gene markers for lung cancer
[0235] The screening of lung cancer characteristic genes includes the following steps:
[0236] 1) Peripheral blood samples were collected from 48 patients with malignant micronodules diagnosed with lung cancer by surgery and pathological examination and 38 patients with benign micronodules (benign lung lesions). All patients with micronodules had nodules less than or equal to 10 mm in size confirmed by CT examination, and 2-3 ml of peripheral blood was collected from each sample.
[0237] 2) Total RNA from the above samples was extracted using the PAXgene Blood RNA Kit, and the fragment integrity (RIN) of the RNA samples was detected using the Agilent Bioanalyzer 2100 bioanalyzer, and the purity of the RNA samples was detected using the Nano1000 micro-volume UV spectrophotometer. All RNA samples must meet the following quality control conditions: RNA yield greater than 2 micrograms, 28S / 18S peak ratio greater than 1, RIN value greater than 7, and absorbance ratio at 260nm / 280nm greater than 1.8.
[0238] 3) The above peripheral blood total RNA samples were detected using Affymetrix Gene Profiling Array U133Plus2 chip (human whole gene expression profile chip) to obtain the peripheral blood gene expression profile data of the samples, and then the peripheral blood gene expression profile data were normalized using the MAS5 method in Affymetrix Expression Console software to eliminate the systematic errors that may occur during the expression profile chip detection process and obtain peripheral blood gene expression profile data that can be uniformly compared.
[0239] 4) Gene expression signals that were too high or too low in the peripheral blood gene expression profile were eliminated, and genes with moderate expression (signal values between 100 and 10,000) in all samples were selected for T-test analysis to compare the differences in peripheral blood gene expression between micronodule lung cancer and benign nodules. Genes with a statistical P value less than 0.05 and a gene expression fold change of more than 1.1 times were selected as candidate genes for subsequent analysis.
[0240] 5) Analyze the correlation between the above candidate genes and micronodule lung cancer, sort the genes according to the correlation coefficient with micronodule lung cancer, and select a group of gene cohorts (gene cohort I) that are highly correlated with micronodule lung cancer; in addition, analyze the correlation between the remaining genes and the genes in cohort I, and select another group of gene cohorts (gene cohort II) that are highly correlated with gene cohort I. Then pair the genes in gene cohort I and gene cohort II to form a series of candidate gene combinations.
[0241] 6) Logistic regression statistical analysis was used to evaluate the ability of each candidate gene combination to discriminate small nodules of lung cancer. The receiver operator characteristic curve (ROC curve) and area under the curve (AUC) of each candidate gene combination were calculated to screen out a series of gene combinations with good discrimination ability for small nodules of lung cancer.
[0242] 7) The screened gene combinations were verified by real-time fluorescence quantitative PCR, and the genes with consistent expression changes in quantitative PCR and gene expression profile chip detection were retained as peripheral blood characteristic genes of micronodular lung cancer. The 14 lung cancer characteristic genes CEACAM4, S100A9, FCGR1A, ROGDI, ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, TARBP1, SMA4, HNRNPD and SMC1A were mainly screened (their gene sequences are shown in SEQ ID NO.1 to SEQ ID NO.14). The significance of the 14 lung cancer characteristic genes is shown in Figure 1. Figure 1 .
[0243] 8) Logistic regression statistical analysis was used to evaluate the diagnostic effect of any combination of 7 genes from the above 14 genes on micronodular lung cancer, the ROC AUC of the gene combination was calculated, and the micronodular lung cancer discrimination model shown below was established:
[0244]
[0245] Among them, σ(z), i.e., P, is the risk value of developing micronodule lung cancer (malignant pulmonary nodules); b0 to b7 are the corresponding logistic regression model parameters; ΔCt1 to ΔCt7 are the differences in the Ct values of the quantitative PCR cycles of the seven micronodule lung cancer gene markers and the internal reference gene; and z is the log likelihood ratio of logistic regression.
[0246] Example 2: Detection of micronodular lung cancer using the screened lung cancer characteristic gene markers
[0247] This example uses a 7-gene combination: HNRNPD, TNFSF10, SLC38A1, MCEMP1, ZFN266, TRAF5, MORF for diagnosis.
[0248] Method steps:
[0249] 1) Collection of peripheral blood samples to be tested: Use BD PAXgene RNA blood collection tubes from QIAGEN to collect peripheral blood samples from patients;
[0250] 2) Extraction and purification of total RNA from peripheral blood samples: Use QIAGEN's PAXgene BloodRNA Kit to extract and purify total RNA from peripheral blood, and use Agilent BioAnalyzer 2100 micro-electrophoresis analyzer to identify the integrity and yield of the extracted total RNA fragments. Use Nano1000 micro-ultraviolet spectrophotometer to detect the purity of RNA samples;
[0251] 3) Reverse transcription reaction: Use the High-Capacity cDNA Reverse Transcription kit from Life Technology Company, use total RNA as a template, and use Oligo (dT) as a reverse transcription primer to perform reverse transcription reaction to synthesize cDNA.
[0252] 4) Fluorescence quantitative RT-PCR detection: This embodiment exemplarily uses a 7-gene panel combination (HNRNPD, TNFSF10, SLC38A1, MCEMP1, ZFN266, TRAF5, MORF, a total of 7 gene combinations) and the relevant sequence of the internal reference gene GAPDH, designs corresponding specific primers and / or probes or uses SYBRGreen dye that can non-specifically bind to the PCR amplification fragment, uses the cDNA obtained by reverse transcription as an amplification template, performs real-time fluorescence quantitative PCR reaction, and uses the GAPDH gene as an internal reference gene (the amplification primer sequence of the internal reference gene GAPDH is shown in SEQ ID NO.57 to SEQ ID NO.58, and the probe sequence is shown in SEQ ID NO.59) to obtain the relative mRNA content of the 6 gene markers in the peripheral blood sample. The following Table 1 lists the fluorescence quantitative PCR reaction system. The following Table 2 lists the primer and probe sequences designed for lung cancer characteristic genes.
[0253] Table 1 Fluorescence quantitative PCR reaction system
[0254] Reagents concentration volume Characteristic gene primers 800nM 2μL Characteristic gene fluorescent probe 200nM 0.5μL Primers for internal reference gene GAPDH 800nM 2μL Internal reference gene GAPDH fluorescent probe 200nM 0.5μL 2×PCR MasterMix 12.5μL cDNA template 2.67 ng / μL 7.5μL total 25μL
[0255] Table 2 Specific primers and probe sequences of lung cancer characteristic genes
[0256]
[0257]
[0258]
[0259] 5) Diagnosis of the results of the samples to be tested: Based on the relative mRNA levels of the seven gene markers HNRNPD, TNFSF10, SLC38A1, MCEMP1, ZNF266, TRAF5, and MORF in peripheral blood samples detected by real-time fluorescence quantitative PCR, the corresponding micronodule lung cancer discrimination model is used to calculate the logistic regression risk value (P) of the sample. The test result with a risk value (P) exceeding the threshold is judged as positive, that is, lung cancer; the test result with a risk value (P) below the threshold is judged as negative, that is, not lung cancer.
[0260] 2. Results
[0261] A total of 114 cases of malignant micronodule lung cancer (Lung Cancer) and 82 cases of benign micronodules (Benign) were collected for peripheral blood samples. Fluorescence quantitative PCR was used to detect the relative expression of 7 gene markers of micronodule lung cancer and the internal reference gene GAPDH in the peripheral blood. The logistic regression log likelihood ratio X value of each sample was calculated. X value ≥ 0 was considered a positive test result, and vice versa as a negative test result. The test results were compared with the pathological test results, and it was concluded that the lung cancer characteristic gene markers of the present invention can better distinguish malignant pulmonary nodules (micronodule lung cancer) and benign micronodules, and the sensitivity and specificity of micronodule lung cancer detection are both over 75%. The specific test results are shown in Figure 2 and Table 3.
[0262] Table 3
[0263]
[0264] Based on 196 sample data, the model constructed with 7 gene markers achieved a sensitivity, specificity, and accuracy of more than 75% in the training set, with an AUC of 0.88; its sensitivity, specificity, and accuracy in the test set also achieved a sensitivity, specificity, and accuracy of more than 75%, with an AUC of 0.7.
[0265] Example 3: Detection of micronodular lung cancer using multiple combinations of screened lung cancer characteristic gene markers
[0266] The same method as described in Example 2 was used to diagnose using various gene combinations, and the results are shown in Tables 4 and 5. Table 4 shows that various gene marker combinations can be constructed based on 14 gene markers. Table 5 shows the sensitivity, specificity, accuracy and AUC of these combinations in the test set and training set. Except for Groups 1 and 2, the sensitivity and specificity of each group in the test set were greater than 60%.
[0267]
[0268]
[0269]
[0270]
[0271] The above-mentioned embodiments only express the implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims. Sequence Listing <110> Shanghai Bohao Medical Laboratory Co., Ltd. <120> Markers for distinguishing benign and malignant pulmonary nodules and their uses <130> 201735 <160> 59 <170> SIPOSequenceListing 1.0 <210> 1 <211> 1205 <212> DNA <213> Artificial Sequence <400> 1 acagaaggag gaaggtcagc agccccgaca gccgacagtc acagcagctc tgacaagagc 60 gttcctggag cccagctcct ctccacagag gacaagcagg cagcagagac catgggcccc 120 ccctcagccg ctccccgtgg agggcacagg ccctggcagg ggctcctgat cacagcctca 180 cttttaacct tctggcaccc gcccaccact gtccagttca ctattgaagc cctgccgtcc 240 agtgctgcag agggaagga tgttcttcta ctggcctgca atatttcaga aactattcaa gcctattatt ggcacaaggg gaaaacggca gaagggagcc ctctcattgc tggttatata 360 acagacattc aagcaaatat cccaggggcc gcatacagtg gtcgagagac agtatacccc aatggatccc tgctgttcca aaacatcacc ctggaggacg caggatccta caccctacga accataaatg ccagttacga ctctgaccaa gcaactggcc agctccacgt acaccaaaac aacgtcccag gccttcctgt gggggccgtc gctggcatcg tgactggggt cctggttggg 600 gtggctctgg tggccgccct ggtgtgtttt ctgcttctct ccaggactgg aagggccagc 660 atccagcgtg acctcaggga gcagccgccc ccagcctcca cccctggcca tggtccctct 720 cacagatcca ccttctcggc ccctctaccc agccccagaa cagccactcc catctatgag gaattgctat actctgatgc aaacatttac tgccagatcg accacaaagc agatgtggtc tcttaggttc ctctgggagc tgctcttgtg ggttgatgga gcgtccccga agctcccagc 900 cctggggacg gggaaggaca tggagcctga gccagagaac cagctctgag tcctgaggag 960 acacaggcct ggggacaggg agggatggga gtccctgctg aatatctgga gaccctgaca 1020 ggttgccctg ggctctgggt gggccgggac aaaggcctct catcaccaca ggaagcgggg 1080 gcttgcaagg aaagtgaatg ggcctgtggc ccacccgggg tcaccaggaa aggatctgaa 1140 taagaggac ccttcctctc attggctctt tttctgctca cgggaactta gcagaaactc 1200 acctg 1205 <210> 2 <211> 573 <212> DNA <213> Artificial Sequence <400> 2 aaacactctg tgtggctcct cggctttgac agagtgcaag acgatgactt gcaaaatgtc 60 gcagctggaa cgcaacatag agaccatcat caacaccttc caccaatact ctgtgaagct 120 ggggcaccca gacaccctga accaggggga attcaaagag ctggtgcgaa aagatctgca 180 aaatttctc aagaaggaga ataagaatga aaaggtcata gaacacatca tggaggacct 240 ggacacaaat gcagacaagc agctgagctt cgaggagttc atcatgctga tggcgaggct 300 aacctgggcc tcccacgaga agatgcacga gggtgacgag ggccctggcc accaccataa 360 gccaggcctc ggggagggca ccccctaaga ccacagtggc caagatcaca gtggccacgg 420 ccacggccac agtcatggtg gccacggcca cagccactaa tcaggaggcc aggccaccct 480 gcctctaccc aaccagggcc ccggggcctg ttatgtcaaa ctgtcttggc tgtggggcta 540 ggggctgggg ccaaataaag tctcttcctc caa 573 <210> 3 <211> 2268 <212> DNA <213> Artificial Sequence <400> 3 aatatcttgc atgttacaga tttcactgct cccaccagct tggagacaac atgtggttct 60 tgacaactct gctcctttgg gttccagttg atgggcaagt ggacaccaca aaggcagtga 120 tcactttgca gcctccatgg gtcagcgtgt tccaagagga aaccgtaacc ttgcactgtg 180 aggtgctcca tctgcctggg agcagctcta cacagtggtt tctcaatggc acagccactc 240 agacctcgac ccccagctac agaatcacct ctgccagtgt caatgacagt ggtgaataca 300 ggtgccagag aggtctctca gggcgaagtg accccataca gctggaaatc cacagaggct 360 ggctactact gcaggtctcc agcagagtct tcacggaagg agaacctctg gccttgaggt 420 gtcatgcgtg gaaggataag ctggtgtaca atgtgcttta ctatcgaaat ggcaaagcct 480 ttaagtttt ccactggaat tctaacctca ccattctgaa aaccaacata agtcacaatg 540 gcacctacca ttgctcaggc atgggaaagc atcgctacac atcagcagga atatctgtca 600 ctgtgaaaga gctatttcca gctccagtgc tgaatgcatc tgtgacatcc ccactcctgg 660 aggggaatct ggtcaccctg agctgtgaaa caaagttgct cttgcagagg cctggttgc 720 agctttactt ctccttctac atgggcagca agaccctgcg aggcaggaac acatcctctg 780 aataccaaat actaactgct agaagagaag actctgggtt atactggtgc gaggctgcca 840 cagaggatgg aaatgtcctt aagcgcagcc ctgagttgga gcttcaagtg cttggcctcc 900 agttaccaac tcctgtctgg tttcatgtcc ttttctatct ggcagtggga ataatgtttt 960 tagtgaacac tgttctctgg gtgacaatac gtaaagaact gaaaagaaag aaaaagtggg 1020 atttagaaat ctctttggat tctggtcatg agaagaaggt aatttccagc cttcaagaag 1080 acagacattt agaagaagag ctgaaatgtc aggaacaaaa agaagaacag ctgcaggaag 1140 gggtgcaccg gaaggagccc cagggggcca cgtagcagcg gctcagtggg tggccatcga 1200 tctggaccgt cccctgccca cttgctcccc gtgagcactg cgtacaaaca tccaaaagtt 1260 caacaacacc agaactgtgt gtctcatggt atgtaactct taaagcaaat aaatgaactg 1320 acttcaactg ggatacattt ggaaatgtgg tcatcaaaga tgacttgaaa tgaggcctac 1380 tctaaagaat tcttgaaaaa cttacaagtc aagcctagcc tgataatcct attacatagt 1440 ttgaaaaata gtattttatt tctcagaaca aggtaaaaag gtgagtgggt gcatatgtac 1500 agaagattaa gacagagaaa cagacagaaa gagacacaca cacagccagg agtgggtaga 1560 tttcagggag acaagaggga atagtataga caataaggaa ggaaatagta cttacaaatg 1620 actcctaagg gactgtgaga ctgagagggc tcacgcctct gtgttcagga tacttagttc 1680 atggctttc tctttgactt tactaaaaga gaatgtctcc atacgcgttc taggcataca 1740 agggggtaac tcatgatgag aaatggatgt gttattcttg ccctctcttt tgaggctctc 1800 tcataacccc tctatttcta gagacaacaa aaatgctgcc agtcctaggc ccctgccctg 1860 taggaaggca gaatgtaact gttctgtttg tttaacgatt aagtccaaat ctccaagtgc 1920 ggcactgcaa agagacgctt caagtgggga gaagcggcga taccatagag tccagatctt 1980 gcctccagag atttgcttta ccttcctgat tttctggtta ctaattagct tcaggatacg 2040 ctgctctcat acttgggctg tagtttggag acaaaatatt ttcctgccac tgtgtaacat 2100 agctgaggta aaaactgaac tatgtaaatg actctactaa aagtttaggg aaaaaaaca 2160 ggaggagtat gacaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa aaaaaaaaaa 2220 2268 <210> 4 <211> 1418 <212> DNA <213> Artificial Sequence <400> 4 agaaagattg gtggacagga gcagcggccg gtggggaggg cgctcggcgg cggcctgcgg 60 ccatggccac cgtgatggca gcgacggcgg cggagcgggc ggtgctggag gaggagttcc 120 gctggctgct gcacgacgag gtgcacgctg tgttgaagca gctgcaggac atcctcaagg 180 aggcctctct gcgcttcact ctgccgggct ccggcactga ggggcccgcc aagcaagaga 240 acttcatcct aggcagctgt ggcacagacc aggtgaaggg tgtgctgact ctgcaggggg 300 atgccctcag ccaggcggat gtgaacctga agatgccccg gaacaaccag ctgctgcact 360 tcgccttccg ggaggacaag cagtggaagc tgcagcagat ccaggatgcc agaaaccatg 420 tgagccaagc catttacctg cttaccagcc gggaccagag ctaccagttc aagacgggcg 480 ctgaggtcct caagctgatg gacgcagtga tgctgcagct gaccagagcc cgaaaccggc 540 tcaccacccc cgccaccctc accctccccg agatcgccgc cagcggcctc acgcggatgt 600 tcgcccctgc cctgccgtcc gacctgctgg tcaacgtcta catcaacctc aacaagctct 660 gcctcacggt gtaccagctg catgccctgc agcccaactc caccaagaac ttccgcccag 720 ctgggggcgc ggtgctgcat agccctgggg ccatgttcga gtggggctct cagcgcctgg 780 aggtgagcca cgtgcacaaa gtggagtgcg tgatcccctg gctcaacgac gccctggtct 840 acttcaccgt ctccctgcag ctctgccagc agctcaagga caagatctcc gtgttctcca 900 gctactggag ctacagaccc ttctgatcac agcacccagg agcttgtctc caggaaggcg 960 gccccgtccc ctactcatac ccaccacaga gcaccagcca gtgccaacgc caggctgcta 1020 tttatctccc tatcccaccc cctaccccac ctaacacatt tgcactgccg ggaatggaca 1080 ctggaagtgc caggaggaag gaaggctggt ttggtggggt agtggggagg tcagggaggc 1140 ggggccaagg gtgtcccaca ttcccaacac cgccctctga tcaccatggg aatctttgga 1200 ctcaggacag ggccaggcgc agggctctcc ctcctctccc cttcgctgtc ccctccccct 1260 ggagggcatg gtgtcggggg gtggcactga gctatgagtc ccggggatgg tgaggaacgc 1320 cacagacaga gccaccctag gagtgagtat agtgctggtg actgtgtttc atagccccag 1380 tccagggctg tctaagaaat aaagatcatc agactcca 1418 <210> 5 <211> 3992 <212> DNA <213> Artificial Sequence <400> 5 gctgtgtttt ccggcgcttt ctccgcgccg ccaaacccgt tttcttcctg gtggcgtttg 60 ggcttaatac agctttggcg aggtcggatg acgggtggga gccagcggtg gaaggggtgg 120 cgaaagtacc ggtttgcccc aggccgccga ggggcctcct tagagagacc ttgcctgctc 180 cgctcgcgtc cgccggggcc gcgcgggtcc tcctggcgcc gccaggttca aaaagccact 240 cgagttgtca ctgcgacggc cctgggccag gagccgtttc gggatctgtc aaacaacgag 300 ttttcgtcgt tcgaatcagg ttgactggtc cttcatcccc ccaatctccc gtacctggcg 360 agtccagctc gtcgcggcct gtacctcccc acagagcttc aaaacgggct tttaggaaga 420 aggaatggag gctttgaagc aatgctaaga aaagagtgat atgcaagctg agaccaaaaa 480 tatggtatga tttagccata ctgaagggga aggaaataag agctgggcaa agcattctgt 540 gaattggctg actccacttc tatggtgaga gaggaggatg catcaaagat tactcccaga 600 gatggtttca gcatgttggc cagtctggtc tcagactcct gacctcaagt gatccaccca 660 cctcggcctc ccaaaatgct gggattacag gtataagcca ctgtgcctgg ccaaagatac 720 cgttaaacct ggataaagag aatggaggtt acctctgtcc gtgtagattc ctaagctgtc 780 ctggagtgat ccttggagta aaggaaaggt gctttgaagc acattcagcc atcagccctg 840 tgggatggca gccactgatt tgtcctatgg tctttacagg gacccagtct gccttcaaga 900 aaagacagaa gtagaaaggg tggtggctga ctgtctgaca aattgttatc aggtatgcag 960 gaagtatatc cttctccaaa atatcatact tgcatcacca ggtagacaca tttccttcta 1020 cacagaatta tcttcagagc ttcttaaagc aaataaagcc tccttcaagg actgagtccc 1080 tagtcgaatt cccggaagga gtggagcctg tcatattggt gagggtttgc cttgaatgtc 1140 atcccagtat ttcaatattg attaattagt cttccctcat ggtcccaact gcatagtttt 1200 tattttgttg agtgttctga cacatggtaa gggacatgaa agtatccttt gagataatct 1260 ttccattcat cagtgttat ctagcatctg ctcaagagtg tgctgcagtg gagggaaatc 1320 agatgacctc ccagtctggt tgtgttacat acaatcatgt gtaagaagtg ccattcaagc 1380 cgtgtcactg gaggggactg acagattcag tgacttttga tgatctggct gtggacttca 1440 ccccagaaga atggacttta ctggacccaa ctcagagaaa cctctacaga gatgtgatgc 1500 tggagaacta caagaatttg gccacagtag gatatcagct cttcaaaccc agtctgatct 1560 cttggctgga acaagaagag tctaggacag tgcagagagg tgatttccaa gcttcagaat 1620 ggaaagtgca acttaaaacc aaagagttag cccttcagca ggatgttttg ggggagccaa 1680 cctccagtgg gattcaaatg ataggaagcc acaacggagg ggaggtcagt gatgttaagc 1740 aatgtggaga tgtctccagt gaacactcat gccttaagac acatgtgaga actcaaaata 1800 gtgagaacac atttgagtgt tatctgtatg gagtagactt ccttactctg cacaagaaaa 1860 cctctactgg agagcaacgt tctgtattta gtcagtgtgg aaaagccttc agcctgaacc 1920 cagatgttgt ttgccagaga acgtgcacag gagagaaagc ttttgattgc agtgactctg 1980 ggaaatcctt cattaatcat tcacaccttc agggacattt aagaactcac aatggagaaa 2040 gtctccatga atggaaggaa tgtgggagag gctttattca ctccacagac cttgctgtgc 2100 gtatacaaac tcacaggtca gaaaaaccct acaaatgtaa ggaatgtgga aaaggattta 2160 gatattctgc ataccttaat attcacatgg gaacccacac tggagacaat ccctatgagt 2220 gtaggagtg tgggaaagcc ttcaccaggt cttgtcact tactcagcac agaaaaactc 2280 acacctggaga gaaaccttat aaatgtagg attgtggg agccttcact gtttccctt 2340 gcttaagtca acatagtgaa atccatgtgg gtgagaagcc ttatgaatgc aaggaatgtg 2400 ggatagcctt cactagatct tctcactta ctgaacttt aaaaactcac actgccaagg 2460 atccctttga atgtaagata tgtggaaaat cctttagaaa ttcctcatgc ctcagtgatc 2520 actttcgaat tcacactgga ataaaaccct ataatgtaa ggattgtggg aaagccttca 2580 ctcagaactc agaccttact aagcatgcac gaaccacag tggagagg ccctatgaat 2640 gtaggaatg tggaaaggcc tttgccagat cctctcgcct tagtgaacat acagaactc 2700 acactggaga gaagcctttt gatgtgtca aatgtgggaa agccttttgct atttctca 2760 atcttagtgg acatttgaga attcacactg gagagaagcc ctttgagtgc ctggaatgtg 2820 gtaaagcatt tacgcattcc tccagtctta ataatcacat gcggacccac agcgccaaaa 2880 aaccattcac gtgtatggaa tgtggcaaag cttttaagtt tcccacgtgt gttaaccttc 2940 acatgcggat ccacactgga gaaaaaccct acaaatgtaa acagtgtggg aaatccttca 3000 gttactccaa ttcgtttcag ttacatgaac gaactcacac tggagagaaa ccctatgaat 3060 gtaaggagtg cgggaaagcc ttcagttctt ccagttcctt tcgaaatcat gaaagaaggc 3120 atgcggatga gagactgtca gcataaggaa tgtgggaaaa cctaaaggtg tccctgttct 3180 ctctgaagac atgaaaactc actggggaga aaccctatga atgtaaaaat gtggaagcaa 3240 ctttgtatct caggtcttaa tgaacacata tgaattcaca gtggagaaga ccctgcatca 3300 gggaatgtgg aaatgacttt gctgaattct caagccttac caaacacatc agaaatctca 3360 ctggagagaa actgtatgaa tgtagagaat ctgggaatac ctttctgaat cccacaaacc 3420 ttaatgtgtg tatgtgaact cacattggag agaaaccctg caatttaaat ggtatggtct 3480 ggatgatgcc ccactccata tttgtaagcc ctaagtccta gttccttaca ctataactgt 3540 atttggacat agggttttca aacaggtgag taacttcaaa tgaggttgtt gggttcgatc 3600 cctaatctga catcactggt gtccctataa gggaaactga aggaaggata cacatggaga 3660 agactgtgtg gatccaccag aagatggcca tctacaagcc aaggacagag acctggaaca 3720 gatgctttca tttggcctc cagaggaaac caaccctgtc tccaccttga tattgcactt 3780 ccaggctcca gaactgtgag gcaataaatt tctcttggtt aaatcattca gtctgttatt 3840 ttgtacagca accctaggaa actaatactg tgaggaactt gggaaaagct ttagatcaag 3900 cttgtccaac ccgcaggcca ggatggcttt gaatgcagac caacacaaat ttttaagctt 3960 tcttcaaaca tataaaat ttttgtgat ta 3992 <210> 6 <211> 1876 <212> DNA <213> Artificial Sequence <400> 6 gaccggctgc ctggctgact tacagcagtc agactctgac aggatcatgg ctatgatgga 60 ggtccagggg ggacccagcc tgggacagac ctgcgtgctg atcgtgatct tcacagtgct 120 cctgcagtct ctctgtgtgg ctgtaactta cgtgtacttt accaacgagc tgaagcagat 180 gcaggacaag tactccaaaa gtggcattgc ttgtttctta aaagaagatg acagttattg 240 ggaccccaat gacgaagaga gtatgaacag cccctgctgg caagtcaagt ggcaactccg 300 tcagctcgtt agaagatga ttttgagaac ctctgaggaa accattcta cagttcaaga 360 aaagcaacaa atattctc ccctagtgag agaagaggt cctcagagag tagcagctca 420 cataactggg accagaggaa gaagcacac attgtctctct ccaactcca agaatgaaaa 480 ggctctgggc cgcaaaataa actcctggga atcatcagg agtgggcatt cattcctgag 540 caactgcac ttgaggaatg gtgaactggt catccatgaa aaagggtttt actacatcta 600 ttcccaaaca tactttcgat ttcaggagga aaaaaaaaaaaaaaaaaaaaaaaaaaaaaca 660 aatggtccaa tatattaca atacacaag ttatcctgac cctatattgt tgatgaaaag 720 tgctagaaat agttgttggt ctaaagatgc agaatatgga ctctattcca tctatcaagg 780 gggaatattt gagcttagg aaatgacag aatttgtt tctgtaacaa atgagcactt 840 gatagacatg gaccatgaag ccagttttt tggggcttt ttagttggct aactgacctg 900 gaaagaaaaa gcaataccct caagtgact attcagtttt caggaatgata cactatgag 960 atgtttcaa aaatctgacc aaaaaaaaaaaaaaaaaacctcta 1020 tgcaatctga gtagagcagc cacaaccaaa aaattctaca acacacactg ttctgaaagt 1080 gactcactta tcccaagaga atgaaattgc tgaaagatct ttcaggactc tacctcatat 1140 cagtttgcta gcagaaatct agaagactgt cagcttccaa acattaatgc aatggttaac 1200 atcttctgtc tttataatct actccttgta aagactgtag aagaaagagc aacaatccat 1260 ctctcaagta gtgtatcaca gtagtagcct ccaggtttcc ttaagggaca acatccttaa 1320 gtcaaaagag agaagaggca ccactaaaag atcgcagttt gcctggtgca gtggctcaca 1380 cctgtaatcc caacatttg ggaacccaag gtgggtagat cacgagatca agagatcaag 1440 accatagtga ccaacatagt gaaaccccat ctctactgaa agtacaaaaa ttagctgggt 1500 gtgttggcac atgcctgtag tcccagctac ttgagaggct gaggcaagag aattgtttga 1560 acccgggagg cagaggttgc agtgtggtga gatcatgcca ctacactcca gcctggcgac 1620 agagcgagac ttggtttcaa aaaaaaaaa aaaaaaact tcagtaagta cgtgttattt 1680 ttttcaataa aattctatta cagtatgtca tgtttgctgt agtgctcata tttattgttg 1740 tttttgtttt agtactcact tgtttcataa tatcaagatt actaaaaatg ggggaaaaga 1800 cttctaatct ttttttcata atatctttga cacatattac agaagaaata aatttcttac 1860 ttttaattta atatga 1876 <210> 7 <211> 7633 <212> DNA <213> Artificial Sequence <400> 7 gtgttatgt ggaagcgaga tgaccggcag gaacctgccc caatgggctg cagagtggtt 60 agtgagtggg tgacagacag acccgtaggc caacgggtgg ccttaagtgt ctttggtctc 120 ctccaatgga gcagcggcgg ggcgggaccg cgactcgggt ttaatgagac tccattgggc 180 tgtaatcagt gtcatgtcgg attcatgtca acgacaacaa cagggggaca caaaatggcg 240 gcggcttagc tcctacccct ggcggcggcg gcagcggtgg cggaggcgac ggcacctcct 300 ccaggcggca gccgcagttt ctcaggcagc ggcagcgccc ccggcaggcg cggtggcggt 360 ggcgcgcagc cagatttgcc tgaagacctg gataatctcc atttttgtca tggactgtta 420 aaacgtttga agttccaatt ctggtcttga tttcccagtt aaagatgttc ttcacccgaa 480 tgcagtcttt cctgttgta aaataagaca accatcaca tgctgttt gtctgctttt 540 gatctctta aggatggatg tttgtaagat gttgcttaat acagtctgga atactctgtc 600 cattgttga attgtaaatg actttcaaat gtgcaagttc tgttaaatac aagagaacc 660 tctatgggta acttttgtgt tgagaagtc atttgtcaac catggtaaa cttgcaaacc 720 cactttatac agagtggatt cttgaagcta tacagaaat aaaaagca aaagcaaggc 780 cctctgaaga gagaatctgc catgcggtca gtactccca tggttggat aagagacag 840 tctctgaaca gctggaactc agtgttcagg atggctcagt tctcaagtc accacaag 900 gccttgccctc ctataaggac ccagacaacc ctggcgctt ttcatcagtt aaaccaggca 960 cttttcctaa gtcagccaag gggtctagag gatcatgtaa tgatctccgc aatgtggatt 1020 ggaataaact tttaggaga gcaatgaag gacttgagga gccgaatggc tcctccctga 1080 agaacataga gaagtatctc agaagtcaa gtgatctcac aagcaccacc aacaacccag 1140 cctttcagca gcggctgcga ctgggggcca aacgcgctgt gatataatggg aggttactga 1200 aagacggacc gcagtacagg gtcaattatg ggagcttaga tggcaaaggg gcacctcagt 1260 atcccagtgc attcccatcc tcgctcccac ctgtcagcct tctaccccat gagaaagacc 1320 agccccgtgc tgatcccatt ccaatatgta gcttctgttt ggggactaaa gaatcaaatc 1380 gtgaaaagaa accagaagaa ctcctctctt gtgcagattg tggcagtagt ggacacccat 1440 cctgtttgaa attttgtcct gaattaacaa caaatgtaaa ggccttaagg tggcagtgca 1500 tcgaatgcaa gacatgcagt gcctgtagag tccaaggcag aaatgctgat aatatgcttt 1560 tttgtgattc ctgtgataga ggatttcata tggaatgctg tgacccacca ctttccagaa 1620 tgccaaaagg gatgtggatt tgccaagtct gcagaccaaa gaaaaaggga agaaaactac 1680 ttcatgagaa agctgcacaa ataaaacgac gatatgcaaa acccattgga cgaccgaaaa 1740 ataaattaaa gcaacgattg ttgtctgtaa ccagtgatga aggatccatg aatgcattca 1800 caggaagggg gtcacctgat actgaaataa aaataaacat caaacaagaa agtgcagatg 1860 taaatgtgat tggaaacaag gatgtcgtta ctgaagagga tttggatgtt tttaagcagg 1920 cccaggaact ttcttgggag aaaatagagt gtgagagtgg ggtggagaac tgtggccggt 1980 acccttctgt gattgaattt ggtaaatatg aaatccaaac ctggtactcc tcgccttacc 2040 cacaggaata tgcaagatta ccaaagcttt acctgtgtga attctgtctt aaatatatga 2100 aaagtaaaaa tattttgcta agacactcca agaagtgtgg atggtttcat cctccagcaa 2160 atgaaattta ccgaaggaaa gacctttcag tatttgaggt tgatgggaat atgagcaaaa 2220 tttattgcca aaacctttgc ttgttagcca agctcttcct ggaccacaaa acgttgtatt 2280 atgatgtcga gccattcctt tttatgtcc ttacaaaaaa tgatgaaaag ggctgtcatc 2340 tggttggata cttctctaag gaaaagcttt gccagcagaa gtataatgtc tcctgcataa 2400 tgatcatgcc ccagcaccaa aggcaaggat ttggacggtt tctcattgat ttcagctatt 2460 tgctttctag aagagaaggc caagcagggt ctcctgaaaa gcctctctcc gatctgggcc 2520 gtctctccta cctggcatat tggaagagcg tcatcttgga gtatctctac caccaccatg 2580 agaggcacat cagcatcaag gcaattagca gagcgacggg catgtgccca catgacattg 2640 ccaccactct gcagcacctc 2700 gacgggaaaa gttgatatg agccacatgg aaagctgaa aacctgttcc agagccaatg 2760 aacttgatcc agacagtctg aggtggaccc caatttaat ttctaatgct gcagtgtctg 2820 aagagagcg agaagctgag aagaggctg agcggctaat ggaacaagct agctgctggg 2880 agaaggagga acaagaatc ctgtcaacta gagctacag taggcaatca cctgcaaag 2940 tacaatcgaa aataaatat ttgcattccc cggagccg gccagtcaca ggggagcgag 3000 ggcagctgct ggagctgtct aaagagagca gtgaagaga agaggag gaggacgagg 3060 Gagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagagg 3120 agaagaagaaaaat attcaagct ctccccag attgacgaa ccacagtcag 3180 ttgccataaa gagaaagagg cctttgtac taaagaagaaagggtcgt aaacgcagga 3240 ggcacacag cagtgtaca acagagacca tttcagagac gagagata ctgaatgagc 3300 cctttgacaa ctcagatgaa gagaggccaa tgccacagct ggagcctacc tgtgagattg 3360 aagtggagga agatggcagg aagccagtcc tgagaaagc attccagcat cagcctggga 3420 agaaaagaca aacagaggaa gaggaagga aagacaatca ttgctcaag atgctgacc 3480 cttgtagaaa caattgaat gatgattcaa gtaacttgaa agaggcagt aaagacaatc 3540 ccgaacctct aaagtgcaa caagtgtggc caaaggaac aaagcgcggt ctactaagt 3600 ggaggcaaa aaagagagg aagaccggat ttaaactgaa ttgtacacc ccgccagaaa 3660 cacccatgga gcctgacgag caggtacag tgagaca gagagact tcagagac 3720 aaaccagccc cagtcccatc aggattgagg aggaggtca ggaactggg gaagccctgt 3780 tgcctcaaga ggaaaacaga agggaaaa catgtgcccc tgtaagtcca aacacatcac 3840 caggtgaaaa accagagat gatctcatca aacctgagga agaggaag gaggaggagg 3900 gagagagagagagagagagagagagagagagagagagagagagagagagagagagagaggtag 3960 aaaaagagatcc agatgtgct aaaagccaag aaaagagga accagaatc tccacggaaa 4020 aagagactc tgcacgtttg gatgatcacg agaggagga ggaaggt gaagagccat 4080 cccacaacga ggaccatgat gccgatgacg aggatgacag ccacatggag tctgccgaag 4140 tggaagg agagctgccc aggaagct txaagagt actggaaac caggactt 4200 ttttagacct taatgtgcag cctggtcact cgaacccaga gttcttaatg gactgtgcg 4260 tcgacctgac agctcttgt aacagtgagc ccaaggagct tgctgggac cctgaagctg 4320 tacccgaatc tgacgaggag ccacccccag gagacaggc acagaagcag gaccaaaga 4380 acahshagga agtcgataca gagttcaag agggaaccc agshaaccatg gaatcgact 4440 ctgagactgt ccaggccgtt cagtcttga cccaggagag cagcgacag gacgacacct 4500 ttcaggattg tgccgagact caaggcct gtagaagcct acagaactac acccgtgcag 4560 accaaagtcc acagattgcc accacgctcg acgattgcca acagtcggac cacagtagcc 4620 cagtttcatc cgtccactcc catcctggcc agtccgtacg ttctgtcac agcccaagtg 4680 tccctgctct ggaaaacagc tacgcccaaa tcagcccaga tcaagtgcc atctcagtgc 4740 catctctgca gaacatggaa accagtccca tgatgt cccatcagtt tcagatcatt 4800 cacagcaagt cgtagacagt ggatttagtg acctgggcag tatcgagagc acaactgaga 4860 actacgaaaa cccaagcagc tacgattcta ctatgggagg cagcatctgt ggaaacggct 4920 cttcacagaa cagctgctcc tatagcaacc tcacctccag cagtctgaca cagagcagct 4980 gtgctgtcac ccagcagatg tccaacatca gcgggagctg cagcatgctg cagcaaacca 5040 gcatcagctc ccctccgacc tgcagcgtca agtctcctca aggctgtgtg gtggagaggc 5100 ctccgagcag cagccagcag ctggctcagt gcagcatggc tgctaacttc accccaccca 5160 tgcagctggc tgaaatcccc gagacgagca acgccaacat tggcttatac gagcgaatgg 5220 gtcagagtga ttttggggct gggcattacc cgcagccgtc agccaccttc agccttgcca 5280 aactgcagca gttaactaat acacttattg atcattcatt gccttacagc cattccgctg 5340 ctgtgacttc ctatgcaaac agtgcctctt tgtccacacc attaagtaac acagggcttg 5400 ttcaactttc tcagtctcca cactccgtcc ctgggggacc ccaagcacaa gctaccatga 5460 ccccaccccc caacctgact cctcctccaa tgaatctgcc gccgcctctt ttgcaacgga 5520 acatggctgc atcaaatatt ggcatctctc acagccaaag actgcaaacc cagattgcca 5580 gcaagggcca catctccatg agaaccaagt cagcgtctct gtcaccagcc gctgccaccc 5640 atcagtcaca aatctatggg cgctcccaga ctgtagccat gcagggtcct gcacggactt 5700 taacgatgca aagaggcatg aacatgagtg tgaacctgat gccagcgcca gcctacaatg 5760 tcaactctgt gaacatgaac atgaacactc tcaacgccat gaatgggtac agcatgtccc 5820 agccaatgat gaacagtggc taccacagca atcatggcta tatgaatcaa acgccccaat 5880 accctatgca gatgcagatg ggcatgatgg gcacccagcc atatgcccag cagccaatgc 5940 agaccccacc ccacggtaac atgatgtaca cggcccccgg acatcacggc tacatgaaca 6000 caggcatgtc caaacagtct ctcaatggct cctacatgag aaggtagaca acgtgggcag 6060 tccacaaaac ctacggggca tcactattgg attgatctgc acaaatacct ttgaagagta 6120 cgatttcaaa accagcaatt ggtgtgaatg caaaaacatt tgttggcacc atttatttaa 6180 aaaaaaaaaa agctgtatgc agcagaaagc cttatacaag ttgtttttct ttttttcctt 6240 tttctttttt ttggtacctt catttctgtt acttttatat aaaattctct gcaaaggaag 6300 gcctctcttt ggactacaat ttggaggcag ccacttgttg tgcctgcttc tgttaaacaa 6360 tgtggatatc aagccccccc aaattatctg ttttaatatt gaacctagag cttttttttt 6420 cccttccctg tccactccat gtaaatgcct ttagcatttc agttattgta tattttgttt 6480 aaggtgacac ttcagcatgc cgctaatgtc tttgttagtg acagtgcatt ttgtagtact 6540 gtacaagtgt tgtgctaaca gtaagccatt tcttaagttt tttgccttga ttagggtgcc 6600 ctaatttgag ggttttaaaa aaaactatat ttttgttaat tataaaactg taaagagcta 6660 taaaagctat tcccatttgg ttagtcaaaa gggttttatt gctaaatgtt tggtgtaaag 6720 ttgagaccct tttccatttt ggtgacagat ttctttgggg aaaaaaggca gctttctgtt 6780 ttataaatgc agacttctgt ttattgaatg aagcatatct cagtgtttat ctgtcaggtt 6840 ttgaaacatt tcatatatgt ccaaatactt ggcaggattt aaaaaaaaat agtgaatttg 6900 gtgtaaagtt gctattttat ggaaatgcct ctaactttac attttcattc catctgtaga 6960 ttttctatc tttataaaat attggagtta ttttttaagg aaaatagaa aagtagcttg 7020 tgaatagctc aaactaagct tacaaatcgc atgtaaaaaa gcaaaaaagt tatttgtgtc 7080 tgttatatt gcttcctttt ttgtagcctt tgtacctgta cagggtgaca gtaagggcca 7140 agcaggagag gcgtaatcct tgtataaaat aggatccagc gacactcttg tatttatctg 7200 ttctcttttt agtcagtcac ttcaaaaaaa caaaaaacaa acaaaaaaa gctgtacatt 7260 ttaacataaa ataaattatg atgagccatt tttagcctct tgtgtcctgt catattatga 7320 ttgatagaga atgaccaatg gaactgtatc atgtgtcacg cctcagaaca catacacatt 7380 ttgggaaaat aaattattta gtgtaaattg gagttatggg attttctgat ttgttttgac 7440 tttggggggag gggttggcaa taaataagag tatatctaa taaaaccatc acatatacca 7500 aatacctatt tataaatta atttataatg gattttaatg cttttcatga aagtttattt 7560 tatgcgagtg cataccttct gtatgccaat cattgtcttt aaaataaagt gaaattgttt 7620 tttaaaaaaa aaa 7633 <210> 8 <211> 1326 <212> DNA <213> Artificial Sequence <400> 8 tggacaatt tgcgggctgg ggaccatgga agtggaggaa atctacaagc accaggaagt 60 aagatgcaa gcaccagcct tcaggcaa gaaacagggg gtctcagcca agaatcaagg 120 tgcccatgac ccagactatg agaatatcac cttggccttc aaaaatcagg accatgcaaa 180 gggtggtcat tcacgaccca cgagccaagt cccagcccag tgcaggccgc cctcagactc 240 cacccaggtc ccctgctggt tgtacagagc catcctgagc ctgtacatcc tcctggccct 300 ggcctttgtc ctctgcatca tcctgtcagc ctcatcatg gtgaagaatg ctgagatgtc 360 caggagctg ctgggcttta aaagggagct ttggaatgtc tcaactccg tacaaccatg 420 cgaagagaga cagagagag gctgggattc cgttcagcag agcatcacca tggtcaggag 480 acattga agagaga cgaattagc aggcaaaaaacthgaca aaggtaca 540 gaaaatcttg gaggtgctgc agaaaatgcc acagtcctca cctcataaa tgagaggaca 600 ttgtggcagc caaagccaca acttggaaga tggggctgca cctgccaacg aagacgggaa 660 atgacccccc ccccccagcc tagtgtgaac ctgcccctcg tcccacgtat agaaaaacct 720 cgagtcatgg tgaatgagtg tctcggagtt gctcgtgtgt gtgtacacct gcgtgcgtgt 780 gtgtgcgtgt gtgcgcgtgt gttcgtgtat gtgcgtgtgt gcgtgcgcgt gtgtgtgcat 840 tttgcaaagg gtggacattt cagtgtatct cccagaaagg tgatgaatga ataggactga 900 gagtcacagt gaatgtggca tgcatgcctg tgtcatgtga catatgtgag tctcggcatg 960 tcacggtggg tggctgtgtc tgagcacctc cagcagatgt cactctgagt gtgggtgttg 1020 gtgacatgca ttgcacgggc ctgtctccct gtttgtgtaa acatactaga gtatactgcg 1080 gcgtgttttc tgtctaccca tgtcatggtg ggggagattt atctccgtac atgtgggtgt 1140 cgccatgtgt gccctgtcac tatctgtggc tgggtgaacg gctgtgtcat tatgagtgtg 1200 ccgagttatg ccaccctgtg tgctcagggc acatgcacac agacatttat ctctgcactc 1260 acattttgtg acttatgaag ataaataaag tcaagggaaa acagcgtcaa aaaaaaaaaa 1320 aaaaaa 1326 <210> 9 <211> 3988 <212> DNA <213> Artificial Sequence <400> 9 agacgcacgt gagggaaatc agatgactgg acttgtagat actaacggtt ctgaagcgga 60 atggcttatt cagaagagca taaaggtatg ccctgtggtt tcatccgcca gaattccggc 120 aactccattt ccttggactt tgagcccagt atagagtacc agtttgtgga gcggttggaa 180 gagcgctaca aatgtgcctt ctgccactcg gtgcttcaca acccccacca gacaggatgt 240 gggcaccgct tctgccagca ctgcatcctg tccctgagag attaaacac agtgccaatc 300 tgccctgtag ataaagaggt catcaaatct caggaggtttt ttaaagacaa ttgttgcaaa 360 agagaagtcc tcaacttata tgtatattgc agcaatgctc ctggatgtaa tgccaaggtt 420 attctgggcc ggtaccagga tcaccttcag cagtgcttat ttcaacctgt gcagtgttct 480 aatgagaagt gccgggagcc agtcctacgg aaagacctga aagagcattt gagtgcatcc 540 tgtcagtttc gaaaggaaaa atgcctttat tgcaaaaagg atgtggtagt catcaatcta 600 cagaatcatg aggaaaactt gtgtcctgaa tacccagtat tttgtcccaa caattgtgcg 660 aagattattc taaaaactga ggtagatgaa cacctggctg tatgtcctga agctgagcaa 720 gactgtcctt ttaagcacta tggctgtgct gtaacggata aacggaggaa cctgcagcaa 780 catgagcatt cagccttacg ggagcacatg cgtttggtttt tagaaagaa tgtccaatta 840 gagaacaga ttctgactt acacagagc ctagaacaga aagaaagtaaatccagcag 900 ctagcagaaa ctataaagaa acttgaaag gagttcaagc agtttgcaca gttgttttggc 960 aaaaatggaa gcttccccc aaacatccag gttttgcca gtcacattga gctcattga 1020 tggctagaag ctcaagtgca tcattatta caatggtta accagcaca aataaattt 1080 gacctgagac ctttgatgga agcagttgat acagtgaaac agaaaattac cctgctagaa 1140 aacaatgatc aagattagc cgttttagaa gaggaacta aaacatga tacccatt 1200 atattcata aagcacagct gagtaaaaat gagagcgat ttaactgct ggaggtact 1260 tgctataatg gaagctcat ttggaggtg acagattaca agatgagaa gagagaggcg 1320 gtggatgggc accagtgtc catcttcagc cagtccttct acaccagccg ctgtggctac 1380 cggctctgtg ctagcata cctgaatggg gatgggtcag ggagggggtc acacctgtcc ctatactttg tggtcatgcg aggagagttt gactcactgt tgcagtggcc attcaggcag agggtgaccc tgatgcttct ggaccagagt ggcaaaaaga acattatgga gaccttcaaa cctgacccca atagcagcag ctttaaaaga cctgatgggg agatgaacat tgcatctggc tgtccccgct ttgtggctca ttctgttttg gagaatgcca agaacgccta cattaaagat gacactctgt tcttgaaagt ggccgtggac ttaactgacc tggaggatct ctagtcactg 1740 ttatggggtg rich ttcttggggc rich catttgatta tcatattgac ctggatttag actcaaagca catttgtatt tgccttttttc cttaacgttt gaagtcagtt taaaacttct gaagtgctgt ctttttacat tttactctgt cccagtttga aacttaaaac tcttagaata ttctcttatt atttatttt ttattttct tgaaagatgg tagtttctt gaagtttttg gggcgtttct cttttactgg tgcttagcgc agtgtctcgg gcactctaaa tattgagtgt tatggaggac acagaggtag cagaatccca gttgaaaatg tttgatatt ttattgttg gcctattgat tctagacctg gccttaagctc tgcaaagcc 2160 atctttataa ggtaggctgt tccagttaag tagtggtga tgtagttaca agatatatat 2220 gctcagtttg gaccttttt tcagttaaat gctaaatata tgaaaattac tatacctcta 2280 agtattttca tgaaattcac cagcagttg caagcacagt ttgcaaggc tgcataagaa 2340 ctggtgaatg gggtaagcat ttcattctt cctgctgaag taaagcagaa agtactgcat 2400 agtatatgag atatagccag ctagctaaag ttcagatttt gttaggttca accctatgaa 2460 aaaaactatt ttcataggtc aaaaatgta aaaaattagc agtttcataa gattcaacca 2520 aaaatata tatacaca cacacataca tatacaccta tatatgtgtg tatacaaca 2580 gttcgaatgt attttggtga cagtaataaa tcaatgtgag gatggataga atttagtata 2640 tgatagagaa atgtcataa atggaataaa ggaatttaca acttgaggag aaaccttta 2700 caatttccta tgggtgtcag aagtactctc agcgaaact gatggctaa acagtactcta 2760 ctattctctg atacttttt ttttgagaca gagttcatt gtcaccagg ctggagtaca 2820 gtggcatgat ctcagctcac tgcaaactct gcctcccgaa ttcaagtgat tctcctgcct 2880 cagcctcctg agtagctggg attacaggcg cccgtcacca cacccaggta atttttgtat 2940 ttttagtaga gacggagttt tgccatgttg gccaagctga tctcaaactc ctgacctcaa 3000 gtgatctgcc cgcctcggcc tcccaaagtg ctgagattac aggcatgacc caccgcgtca 3060 agcctctgac aactattgaa tttgtaagct gctatgcaaa tgggcattta tataaacttg 3120 tgatgtttct tgtcagaatt ctgagtactc tgtgaagaac agaaatgatc atattcttat 3180 gcatctatct gtatgggtct gaaggtgtat atacaaactg agatgagtcc ttatgactct 3240 tgataagcct gagtttaaca acaacaaaaa tgccaagttg tcctgagccc ttctgcgttg 3300 ttatgccact tccctactgc tcatatgcac gctggctccc ctgggcacgc aaggatgagt 3360 atgggccatg ggcccctgta gagctgctta cctggtgatg accatgcacc ttacaatttc 3420 tgaacagtta accctataga agcatgcttt atatgagtgt cttctgggaa gaggaacctt 3480 cttaatctct tctgtgggat tttcaaaatg ctaaagactc acactgcagc aatcatccca 3540 3600. 3600. 3600. 3600. 3600. 3600. 3600. 3600. 3600. 3600 ctgctggtga actgtggcac ggttgctcaa cacatcacct cggacaaatt caggaagcat ttctttagcc cacaagtcca gacccaggtg ctctgtatgt ttgtttttaa tattcatcat atccaagttc actctgtctt cctgagcagt ggaagatcat attgctgtaa cttcttttaa gtagttgatg tggaaaacat tttaaagtga atttgtcaaa atgctggttt tgtgttttat ccaacttttg tgcatatata taaagtatgt catggcatgg tttgcttagg agttcagagt tccttcatca tcgaaatagt gattaagtga tcccagaaca aggaatacta gagtaaaaag cacctctttt tcacaaaaa aaaaaaa <210> 10 <211> 7758 <212> DNA <213> Artificial Sequence <400> 10 actgacacgc agctttggtt aaagagcggg cgcacaggag gggaggac cgcgcgcggg acggggagga atggcctgtc cgcgttaac catcacaagc catggttgcg gaagggccac gcgtccccca gtaggagaat gactccgatt cgtgaccctc agcgccggtg catgtcgata 180 tatttattga gtgtctactg tgtgccaggc actatatcta tgtgcataga aaaccctgg 240 aaggccatac aacaatatat atagagtgat cgtctctgct tgctgagcta acaggggtgt 300 caagcttcca ttttggtatc tacttctaaa tacactcaga acaggagaaa tttggactaa 360 ttttcaaact acagacactt tctaatcatg atgcatttca aaagtggact cgaattaact 420 gagttgcaaa acatgacagt gcccgaggat gataacatta gcaatgactc caatgatttc 480 accgaagtag aaaatggtca gataaatagc aagtttattt ctgatcgtga aagtagaaga 540 agtctcacaa acagccattt ggaaaaaaag aagtgtgatg agtatattcc aggtacaacc 600 tccttaggca tgtctgtttt taacctaagc aacgccatta tgggcagtgg gattttggga 660 ctcgccttg ccctggcaaa cactggaatc ctactttttc tggtactttt gacttcagtg 720 acattgctgt ctatatattc aataaacctc ctattgatct gttcaaaaga aacaggctgc 780 atggtgtatg aaaagctggg ggaacaagtc tttggcacca cagggaagtt cgtaatcttt 840 ggagccacct ctctacagaa cactggagca atgctgagct acctcttcat cgtaaaaaat 900 gaactaccct ctgccataaa gtttctaatg ggaaaggaag agacattttc agcctggtac 960 gtggatggcc gcgttctggt ggtgatagtt acctttggca taattctccc tctgtgtctc 1020 ttgaagaact tagggtatct tggctatact agtggatttt ccttgagctg tatggttttt 1080 ttcctaattg tggttattta caagaaattt caaattccct gcattgttcc agagctaaat 1140 tcaacaataa gtgctaattc aacaaatgct gacacgtgta cgccaaaata tgttaccttc 1200 aattcaaaga ccgtgtatgc tttacccacc attgcatttg catttgtttg ccacccgtca 1260 gtcctgccaa tttacagtga gcttaaagac cgatcacaga aaaaaatgca gatggtttca 1320 aacatctcct ttttcgccat gtttgttatg tacttcttga ctgccatttt tggctacttg 1380 acattctatg acaacgtgca gtccgacctc cttcacaaat atcagagtaa agatgacatt 1440 ctcatcctga cagtgcggct ggctgtcatt gttgctgtga tcctcacagt gccggtgtta 1500 tttttcacgg ttcgttcatc tttatttgaa ctggctaaga aaacaaagtt taatttatgt 1560 cgtcataccg tggttacctg catactcttg gttgttatca acttgttggt gatcttcata 1620 ccctccatga aggatatttt tggagtcgta ggagttacat ctgctaacat gcttattttc 1680. attcttcctt catctcttta tttaaaaatc acagaccagg atggagataa aggaactcaa agaatttggg ctgccctttt cttggggcctg ggggtgttgt tctccttggt cagcattccc 1800. ttggtcatct atgactgggc ctgctcatcg agtagcg aaggccactg aaacccgccg 1860. agaaaaagaa acatccctgt tgtctgctca gtcaagtccc cacacatcag caatctctca ccacttcttt tgcaagttta cagaagcaaa cagaaatgta caggatactt aaaatggaat aactttttgg ttgcaaaaca gagacatggt tctataatgc ttcatgtccc tccaagattt gagatcaatt tagggattgt gaatttttt tttcaaattt catacaatca tatttcccag tacttttcac aatcattttt tacccatcta actctatgtt ttgtggcttc ccggtctctt 2220. 2220. 2220. 2220. 2220. 2220. 2220 aattttccta ctgatgttca gctcacacta tctgtacctt tttagaagag aaaagaatct tgaattgtat atatttattt tgctttacag aaaaaaatgg tttcgtaaat aatttgccta ttttggttaa catagcacat ggagataatc atctgaaagt tatagggcac tgccactgct 2400 gaatcagagc atgcccaata tttgaggtgg ctctgatttc ctggcagctg aactcgggta 2460 gtccagtggc ctagctggta ccacatctat tcccatccag agacattctc tggcaagtgt 2520 tctcagctga aaagtggttg gggatgattc ttaccttggt aattaaatga agctacacat 2580 ttgggtaatc tagcaaatga agtatttttt ccctcttggc aacttgtgtc agagttactc 2640 tggtctgagt caactttcgc tggggaaaac ctatggaacc tactgcaaaa agattgtcca 2700 aaatgcctaa gaaaatactc ctctgatgca tttagccttc aaccctacct gtcttgctga 2760 agggagaaaa atgttttagt acattatagg cccagcagct tttattcatg tccaccagct 2820 agttgcacag agaatcatgt gtacctaact aaggatgatc taggataagt aactcctgtt 2880 ttatattgag tattttaggg aagtctttaa aagacttgtt ttatatctat aaatctaggt 2940 tattacaaat acaagaattt tgtaccttaa ataagcctca tttctatttc ttcttcatta 3000 attctccatc tagtcttgtg aaaaaaaaa aaaaaaaacc ctcagagata gtctttgtga 3060 agagcttctg acagaatcac tgagtacctt ccttccccca gatgaggaag acaagggggt ctcagtgtct gtgctgtctc ctcttctctt ccccaaccaa ggactgtgcc attactgccc 3180 gtctcaactg tccatgcagg aggacagagt tgcctggtac tcttaccctt gtccctctcc 3240 taaagggagc acaaggaac tgaagagact gaaaaagaag aggtttgta gctgaaaaag aatgggata gcaaggaac ccagaactgc attcccctaa gtggggccat cccatgtgat tgaattgtcc atagcttgcc tatggtgaga aatgtgcatg ctccgtgagc tggtctcttg 3480. aaacaggact tatgcttcct ctatattctg gttaaatttt ccaaacacat aagttcactg to be tcttatccag to be aatctaaccg to begttg gcagagtttc caggcactta gccatgttcc cttcctgact caaatcccca aaggccttca ctctcactga gaatcacact actgtcccat agataaggca ggcattgaag cacctgtcgt gatcctctag gggggagaat gaaaggttat ttcctgcatt gcatcatcat agcttttaat ataatgctac agaatcatat ccacattagg ttagagttca gatatttgga tatgaatacc taacctagcc atatccatgg ccatctctgt tctttcagc atgttttcc atattatt agcaatgaca 3840 gaacagaac aagccagat ccagtcagtt cttgggagct tgtctagagc accaagtaat 3900 gaaatagcca ggtagtggga tgactgtacc tttaaaaata cataatttag tttgcaagct 3960 atattatgct actttctatt ttccttgtta ctttatagca attcatttta ccctcacaaa 4020 gtcaatttag aaccttatca ttactggga tgtgtagtga tattttggg cctctggtt 4080 tcatgtgtca atacaggaa tatttattta aaatagattt atttagagga ggcacagtgt 4140 tgttgatctg tgtgacacca cccatatttt taaaaacctt tgtatgtttc tctaaatttg 4200 ttgttgactg atatatag accctaccat aattcgtcaa atcactga ttagttacat 4260 cctttgtgtg agattagctg taaagtatac tgctcttatt cttattcaga atagttaatt 4320 ggtagccaaa atacatgta tcacagatgt taggtcgaat ttaaacagca cagtcaagtg 4380 ctatggaagt tttctgcta aattagtaga ttaagaata ctatacccta ggcatgggga 4440 gcagcacgtt ttccttgt aggtaggatc tctatactag tgaacagtgc cagttccaca 4500 ctttggactt agaactgttc tctagttatt gtaacacaga atactgtcaa tccctaattt 4560 acttaatgtt acttattgga agtggggctg atgaatacg cacaggaggg aaatctactg 4620 tgtttaggca caggcagccc cagtgtataa ggagatcata ttccaaagg ttgtcagttg 4680 gttgtttgca acctggaatg tattttcctt tagagaccag gttatccatg gtggttaggc 4740 ccctagagca gctggaaaag atgatcaaac caataggtta gctgacatcg ataatgtaa 4800 taggtttgct aaagaatcta accatcaaat atatattgt ttccaggag ggtgtttgtt 4860 cagagttgcc tgttagtaga atctggactg tccatcccag ccacatccca cctactggac 4920 agtagggta gagatgccac cagactacag gtgaccagat tggcctgaaa catggtgtcc 4980 agtaaaaacg gggaggaata agtccatgac tgctggagag cttggtggta ggaggaggtt 5040 gaggaggggt gaggggggct ctcatgggtc agaacctcc agggacatcc ctcagctggt 5100 aactctgctg ttgtccggag gttcaggct tggtgtgcct tctctgttt gtctgactt 5160 tggctcctat ggttcatctc ctgccctgcc caccacagaa aaggatgctg ctgcatagct 5220 tctccaatgt accagtcatt gaggccagcg cgcagcactt ttaatgtttt tagtgctagt 5280 aactgtgttt taactcca ggaataagct gggaggttag aaaaacaagaa aaaggggga 5340 aaaaaaaac 5400 agcacccaga tgggtgg tgatagggct tgtggtggac acaggttgt ggtaagattc 5460 ctcagtgctt cggcgagcac ctagactat taccctggaa ctgactgctt tctagagctt 5520 gattcatgcc tctaagccag tggttctca agtgtggcc ctagaccagt agcatcagca 5580 tcatcgggga cctcattaga atgcagatc tcagccccct cccagacatg gtgaagtcag 5640 aagctctcag ggagggactc agcaatgat tctaaagcgc atcaagttg agaaccacccc 5700 taagccaatg agtctccctt ttactccca ttagtcctcc ctcaccagat gattcctagg 5760 actcatggtg siacatacag gagccaggct ttagggaggg gaggaaagga gcctggcggc 5820 aggggtctct gcaatggcaa gaagtgagt gatccagcg ctgccacctg gttatcccct 5880 tctcgttgaa atagcagcg caggtgcaaa ttcctaaaca caggctgcct gcactcggtg 5940 ttacctcggg ctgaggcatg tttttttt attttttaaa gctgtgagga aatgaaagtg 6000 aggctttggt tggggcgagg cagttgtgaa agaaattaaa ataaagacc ctttgtaaat 6060 gcagacttag aagaaatact gaatttgtgt cagaagttct ccagtgtttg tgttaatcgt 6120 gtggtgataa tcctgtcctc cttttaaagc gaattctcta ctgaaaggtc tgctctgctt 6180 aaggagctac aaactgctct caaaagaatg aaatactgag ttccaattca gtgaggcaca 6240 gtgttggact atggcacatt tagttggagt cgggggagg tcaggaatat gatcagataa 6300 tggattttat accttagagc aaaatctatt agtctctctc agtttatcaa tttaaatggc 6360 tttaggctta tagggggtgt aaactttaag aatataattc tcccattcaa gtttacagca 6420 aacatctagc caccttcaaa acaaagaata tacagaccat catttagcaa tactaataca 6480 tgattttcct tggggatggc aggtttgaga atcctttagc aacaggacat acttccccta 6540 aattacagtg aattatttat aacgagataa agctttcagg tacaagctga aggtggggtg 6600 tctaacaact aaaaactatc actaaatctc aaaagaaaag ttcttgcaaa atatgtaaag 6660 ttcacaggt gcagacattt tccttcttta ggcttttac taaggaaggg ctatgaaact 6720 gggcccatct gtatacaggc tcaatttac gttttaag gagaatcta tgcagctgag 6780 gcttattgca ggaaatactt cattgtatg taaatattat tgtaataaa taggaggctg 6840 tatattttg aagttgttga tctgcactga atagaagtc tctaggactct gcatataaac 6900 aaaatgtt tcctagaat tagtggtttt gttttgggaat tagaaaatt tacattctct 6960 cccaggtaac atagttctct caatgtaaac ttggaacctg aaaccctact taatttagag 7020 aaagaaatgt ctgagaaata gttcccttga ttctttagc tggcattaag atcattatt 7080 taacagatag tcctctgaga tacaagtaag gatatttag acacaatcc ttgtcctata 7140 gaacagata tacccaatg acaattgtt tctcataat gatcttccat ttttacact 7200 gataccacta cacagtacat atgaaacag aagctgggga gaagaatgtt ttttcacaa 7260 ttgaattgct gcattctca aactttggga tctatgaag cggggagagg gaacctgaat 7320 attaattg agcacaatt tgaggaag aaaaaaaaaaccattactt atcaagctt 7380 tgaaagtcct gcatgtttgc cttttatttt agtgttgacg ccaacataga ctgtctaagg 7440 tatttttttc cccaaacact tgaatcttgg tcgttggtat gtaatccact ctctagagtc 7500 cagtgtactt tagacttcat ctgagtccaa tacatgtacc acactactgt tttattaatg 7560 taaaaacctt gtaaatgaat ttcagatggg tgatttaagt gagtcacaag tcacaaaact 7620 ttgctattca tagttaatca aatagaactg ggtttttttt ttcagagtgt ggtgtaaata 7680 aagaaatata agaagttctg ttctataact gctctgttaa catagttttt aaacattaaa 7740 aaatgtgaac taaaagta 7758 <210> 11 <211> 5206 <212> DNA <213> Artificial Sequence <400> 11 cggtcctgtg cgcacgcatc gcacacgccg gcgccttcct ttgggagccc gggccggtgg 60 cgcgggcgct cggcaaatgg agtgggtgct cgcggaagcg ctgctctcgc agagccggga 120 cccccgggcc ctgcttgggg cgctgtgcca aggggaggca tccgcggagc gcgtggagac 180 gctgcgcttc cttctgcagc ggctcgagga cgaggaggcg cgcggcagcg ggggcgcagg 240 cgcgctcccg gaggcggcgc gcgaggtggc tgcagggtac ctcgtgccac tgctgcggag 300 cctgcgcgga cgccccgcgg gcggcccgga ccccagtctg cagcctcgcc accgccggcg 360 cgtgctgagg gcggcggggcg cggccctgcg ctcgtgcgtc cgcctggccg ggcgtccgca 420 gctggcggcc gcgctggctg aggaggcgct gcgcgatctg ctcgccggggt ggcgcgcgcc 480 tggcgccgag gctgccgtgg aagtgctagc agccgtcggg ccatgtttgc ggccccgcga 540 ggacgggccg ctactggagc gcgtggcggg gaccgccgtc gccctggcgc tgggcgggggg 600 cggggacggg gatgaggccg ggcctgccga ggacgcggcg gcgctggtgg ccggggcgact 660 gctgccagtg ctggtccaat gtggcggggc ggcgctgcgg gccgtgtggg gcgggctggc 720 cgcgcctggg gcgtccctgg ggtccggccg cgtagaggag aagctgctgg tcctgagcgc 780 cctggccgag aagctgttgc ccgagcccgg cggcgaccgc gcccgcggcg cgcgcgaggc 840 gggcccggac gcccggcgct gctggcgctt ctggaggacg gtgcaggcgg ggctgggcca 900 ggcggacgcc ctgacgcgca agcgagcgcg ctacctgctg cagagggcgg tggaggtgtc 960 ggcggagctg ggggccgact gcacctgcgg gccccaggaa ggaaacggcc caagtctgtt 1020 ttggtggtct gagaggaaaa aagatgagct tctaaagttt tgggaaaatt atattttaat 1080 tatggagact ttagaaggaa atcagataca tgttataaag ccagttttac caaagctaaa 1140 caatctgttt gaatatgcgg tgtcagagga aaatggatgt tggctctttc acccatcctg 1200 gcatatgtgt atttataaaa gaatgtttga aagtgaaaac aaaatcctgt ccaaagaagg 1260 tgttatccat tttttggagc tgtatgaaac aaagattctt ccattttcac cagaattttc 1320 tgagtttatt attggaccat taatggatgc gctttcagag agctctctgt atagcaggtc 1380 cccaggccag ccaataggaa gctgttctcc attgggactg aaattacaga agtttttagt 1440 cacttatatt tctcttcttc cagaagaaat aaagagtagc ttcctattga agtttattcg 1500 gaagatgaca agtaggcatt ggtgtgctgt tcccattttg tttctatcta aggctttggc 1560 aaatgtccca agacataagg ccctgggtat agatgggctt cttgctctca gggatgttat 1620 tcattgcact atgatcacac atcagattct cctgagaggg gcagcccaat gctaccttct 1680 tcaaacagct atgaatttgc tagatgtgga gaaagtgtca ctttctgatg tctcaacttt tctcatgtct ctgagacaag aggaatcctt aggagaga acttcattgt ggacagagct gtgtgactgg ctacgtgtta atgaaagcta ttttaagcca tcccctacgt gtagctccat tggacttcac aagacatctt taaatgctta tgtaaagagc attgttcaag agtatgttaa gtcatctgct tgggaaacag gagaaaactg ctttatgcct gattggtttg aagccaagct tgtttctctg atggtcttgc tggctgtgga tgtggaagga atgaagactc agtatagcgg aaagcagaga acagagaatg tattgcggat attcttagac cctcttctgg atgtgcttat gaagtttagt accaatgcct acatgccctt gctgaagact gacagatgcc tccagctgct gttgaagctg ttgaacacat gcaggttgaa aggttccagt gcccaagatg atgaggtgtc tactgttctt cagaactttt tcatgtctac tacagagc atttctgaat ttattctcag aagacttact atgaatgagc taaatagtgt ttcagatctg gatcgttgcc atttatacct gatggtgtta actgagctta taaatctgca tttgaaggtt gggtggaaaa ggggtaaccc tatctggaga gttatttctc ttttgaaaaa tgcatccatt cagcatcttc aagagatgga 2460 2520 ggccatggtg tgtgaggcca tagaccagaa gcctgagctg cagctggact ctctccatgc 2580 tgggcccctg gaaagcttcc tttcctctct tcagctcaat cagacgctgc agaagcccca 2640 cgcagagg cagagcagtt atgctcaccc cttggagtgc agcagtgttt tggaagaatc 2700 gtcatcttcc caaggatggg gaaaaatagt tgcacaatat attcatgatc aatgggtgtg 2760 cctctctttc ctgttgaaaa aatatcacac ccttatacca accacaggga gtgaaattct 2820 ggaaccgttt ctacctgccg ttcagatgcc aataaggact ttgcagtctg cactagaagc 2880 cctcacagtt ctttcttctg atcaagtttt accagtgttc cattgcttga aagtgttggt 2940 tcccaagctt ctgacttcct ctgaatcact ctgcatagag tctttttgaca tggcgtggaa 3000 aattatatct tctttaagca acactcagct gatatctgg gctaatttaa aagcttttgt 3060 tcagtttgtt tttgataaca aagttcttac cattgctgcc aaaatcaagg gccaggcata 3120 tttcaaaata aaagagatta tgtacaagat aattgaaatg tctgctataa agactggagt 3180 cttcaataca ctgataagtt actgctgtca gtcttggata gtgtctgctt caaatgtgtc 3240 ccaaggatct tttcaagtg ctaaaaatta tagcgaactt atccttgagg cttgtatatt 3300 tggaactgtg tttaggcgtg atcaaagact tgttcaggat gtacagacct tcatagaaaa 3360 ccttggacat gactgtgcgg caaatattgt tatggaaaat actaagagag aagaccatta 3420 tgtgagaatt tgtgctgtca aattcctgtg tttattagat ggctccaata tgtcccacaa 3480 gttgtttatt gaggatcttg caatcaagct attagataaa gatgaattag tgtccaagtc 3540 caaaaaacgc tactatgtga attctctaca gcacagagtg aaaaaccgag tgtggcagac 3600 tctgctggta cttttcccta gacttgacca gaatttcttg aatggaatta ttgacaggat 3660 tttccaggct ggtttcacca acaatcaagc atccataaaa tattttatag aatggattat 3720 tatattgatt cttcataaat tccctcaatt tcttccaaag ttctgggatt gtttttctta 3780 tggtgaagaa aatcttaaaa caagcatttg tacgttttta gcagttttat cacatttaga 3840 cattattact caaaatattc cagaaaagaa actaattctg aagcaagccc ttatagttgt 3900 gctgcagtgg tgtttcaatc acaattttag tgttcgactg tatgctttag ttgctcttaa 3960 gaaactctgg actgtgtgta aagtgttaag tgttgaagaa tttgatgccc tgactcctgt 4020 gattgaatcc agcctccatc aagtggaaag catgcacgga gcagggaatg ccaagaagaa 4080 ttggcaacgc attcaggagc attcttttt tgcaacattt caccactca aggattattg 4140 tctagagacc atattttaca tccttccacg cctttcaggc cttattgaag atgaatggat 4200 caccattgat aaatttacca gattcactga tgttccttta gctgcgggat ttcagtggta 4260 cctttctcaa actcaactta gtaaactaaa accaggtgac tggtctcagc aagacatagg 4320 tactaatttg gtcgaagcag ataaccaagc ggagtggacc gacgttcaga agaagattat 4380 cccgtggaac agtcgtgttt ccgacttaga cctggagctc ctgtttcagg atcgtgctgc 4440 cagacttgga aagtcaatta gtagactcat cgttgtggcc tcgctcatcg acaaaccgac 4500 caatttagga ggactgtgca ggacctgtga ggtatttggg gcttcagtgc tcgttgttgg 4560 cagccttcag tgtatcagcg acaaacagtt tcagcacctc agtgtcttg cagaacagtg 4620 gcttcctcta gtggaggtaa aaccacctca gctaattgat tatctgcagc agaagaaaac 4680 agaaggttat accatcattg gagtggaaca aactgccaaa agtttagacc taacccaata 4740 ttgctttcct gagaaatctc tgctcttgtt gggaaatgaa cgtgagggaa ttccagcaaa 4800 tctgatccaa cagttggacg tttgtgtgga aattcctcaa cagggcatta tccgctccct 4860 gaatgtccat gtgagtggag ccctgctgat ctgggagtac accaggcagc agctgctctc 4920 gcacggagat accaagccat gatgtgcctt ccttagtgaa ctgctgctgc tgttcagact 4980 ttttaaaaa aaactatttg gactaaagaa acagattctg aaatttattg tgataatttg 5040 tatttcttt ttcttgcaat ttaatgccaa aagtttgcca tgtgccttaa acatattact 5100 atatattttc ccctttaata aacacttttt gttaaattgt attcttcctt tataaaata 5160 ttttaagcaa ttgtggaaat aaaacaatgg atttttaag agagaa 5206 <210> 12 <211> 1551 <212> DNA <213> Artificial Sequence <400> 12 gtcaaccgcc caacggctga ggagtgcggc agcgcgcg agactggcgg gcagctccgc ccgcggccgg gatgcactag gcaaagccag ctgggctcct gagtccggtg ggtacttgga 120 180. gaacttacta cgtctagctg gaggattgta aatgcaccaa tcagcatgct gtgtctagct caagaactca agctccatga ggagatgttt cattgtcgag agcagtcatg atggcctgca 300. ctccacacaa tgcaacagag tgaaagagca ggttctgctt ctttggtgta gtcctgaagc ttcctaagaa acttcacatc aggtgatgga taggagcaac cctgtaaaac cagccttaga ctattttca aacaggctgg tgaattacca gatctccgtc aagtgcagta accagttcaa gttggaagtg tgtcttttga atgcagaaaa caaagtcgtg gacaaccagg ctgggaccca gggccagctg aaggtgctgg gtgccaacct ctggtggccg tacctgatgc acgaacaccc 540 cgcctacctg tactcgtggg aggatggtga ttgctcacac caaagccttg gacccctccc 600 agcctgtgac ctttgtgacc aactccacct acgcagcaga caagggggct ctgtatgtgg 660 atgtgatccg tgtgaacagc tactactctt ggtatcgcaa ctacgggcac ctggagttga ttcagctgca gctggccgcc cagtttgaga attggtgtaa gatacacaa tcccattatt 780 cagagcgcgt atggagtgga aacgctgta gggcttcacc aggtaagcgg tgttgaactt 840 tctgcttgtg tattctct gggcagagat gccacttgcc tcccacca tgccatctct 900 gagaatatt acagaccatt ttaggagcatg gtgataaga aattttcacc ttaggattc 960 agttgaatag tcattttat atttgtgact gcaagtcact cttaggggct gtacttcctt 1020 agtactgta gcattattat ccaatggact ttatagctt tcattaggtt ttctttgtt 1080 tttgttcttt aagaacgtt ttacttatct tagtatttca tttttcatct atattatgag 1140 gcagtaagag tcttctgttt ttccaagtt gagactgctt tatattat tcgtattgtc 1200 tacagctgta gtgttcaata cattagccac tagccacatg tggttatta ataagataa 1260 aaaaaatt ggccggcgt ggtggctcac gccggtaatc ccaccacttt gggaggccga 1320 ggcgggcaga tcattaggtc aggagatcga gaccatcctt actaagacgg tgaaccccca 1380 tctctattaa aaatacaaaaattagccgg gcgtgtggc gggcgcctgc agtcccagct 1440 actcaggagg ctgaggcagg agaatggcgt gaacctggga ggcagagttt gcagtgagcc 1500 gagatggcgc cactgcactc cagcctgggg gacagagcga gactccatct c 1551 <210> 13 <211> 3068 <212> DNA <213> Artificial Sequence <400> 13 gtcggccatt ttaggtggtc cgcggcggcg ccattaaagc gaggaggagg cgagagcggc 60 cgccgctggt gcttattctt ttttagtgca gcgggagaga gcgggagtgt gcgccgcgcg 120 agagtgggag gcgaaggggg caggccaggg agaggcgcag gagcctttgc agccacgcgc 180 gcgccttccc tgtcttgtgt gcttcgcgag gtagagcggg cgcgcggcag cggcggggat 240 tactttgctg ctagtttcgg ttcgcggcag cggcgggtgt agtctcggcg gcagcggcgg 300 agacactagc actatgtcgg aggagcagtt cggcggggac ggggcggcgg cagcggcaac 360 ggcggcggta ggcggctcgg cgggcgagca ggagggagcc atggtggcgg cgacacaggg 420 ggcagcggcg gcggcgggaa gcggagccgg gaccgggggc ggaaccgcgt ctggaggcac 480 cgaagggggc agcggccgagt cggaggggggc gaagattgac gccagtaaga aggaggagg 540 tgaaggccat tcaactcct ccccacgaca ctctgaagca gcgacggcac agcgggaaga 600 atggaaaatg ttataggag gccttagctg ggacactaca aagaagatc tgaaggacta 660 cttttccaaa ttggtgaag tgtagactg cactctgaag ttagatccta tcacaggggcg 720 atcaggggt tttggctttg tgctatttaa agaatcggag agtgtagata aggtcatgga 780 tcaaaagaa cataaattga atgggaggt gattgatcct aaaagggcca aagccatgaa 840 aacaaaagag ccggttaaa aaatttttgt tggtggcctt tctccagata cacctgaaga 900 gaaaataagg gagtactttg gtggttttgg tgaggtggaa tccatagagc tcccatgga 960 siacaagacc aagaggc gtgggttctg ctttattacc tttaggag aagaaccagt 1020 gagagata atggaaaag ataccacaa tgttggtctt agtaatgtg aaataaagt 1080 agccatgtcg aaggaacaat atcagcaca gcacagtgg ggatctagag gaggatttgc 1140 aggaagct cgtggaagg gtggtggccc cagtcaaac tggaaccagg gatatagtaa 1200 ctattggaat caaggctatg gcaactatgg fathercagc caaggttacg gtggttatgg aggatatgac tacactggtt acaacaacta ctatggatat ggtgattata gcaaccagca gagtggttat gggaaggtat ccaggcgagg tggtcatcaa aatagctaca aaccatacta aattattcca tttgcaactt atccccaaca ggtggtgaag cagtattttc caatttgaag attcatttga aggtggctcc tgccacctgc taatagcagt tcaaactaaa ttttttgtat caagtccctg aatggaagta tgacgttggg tccctctgaa gtttaattct gagttctcat taaaagaaat ttgctttcat tgttttattt cttaattgct atgcttcaga atcaatttgt gttttatgcc ctttccccca gtattgtaga gcaagtcttg tgttaaaagc ccagtgtgac 1680. agtgtcatga tgtagtagtg tcttactggt tttttaataa atccttttgt ataaaaatgt attggctctt ttatcatcag aataggaaaa attgtcatgg attcaagtta ttaaaagcat aagtttgga gacaggcttg ccgaaattga ggacatgatt aaaattgcag tgaagtttga aatgttttta gcaaaatcta atttttgcca taatgtgtcc tccctgtcca aattgggaat gacttaatgt caatttgttt gttggttgtt ttaataatac ttccttatgt agccattaag 1980 atttatatga atattttccc aaatgcccag tttttgctta atatgtattg tgctttttag 2040 aacaaatctg gataaatgtg caaaagtacc cctttgcaca gatagttaat gttttatgct 2100 tccattaaat aaaaaggact taaaatctgt taattataat agaaatgcgg ctagttcaga 2160 gagatttta gagctgtggt ggacttcata gatgaattca agtgttgagg gaggattaaa 2220 gaaatatata ccgtgttat gtgtgtgtgc ttatttgttt gaatgatttt attttccatt 2280 tctcaaaggt tttatttttt tggttagggc cttaaaattt caggactgtg attattagta 2340 tgtgtgccta aggaactttt tgagtcactc ttaagaaagt gaaactgaag agtctaagtg 2400 ataactatag gattaagtca gaattgtttt tcctgtcatt tgttggaagc ttcttgagtt 2460 ctgttattag cattcaggga attgataccc atcaacttga atggaaaatc gtttgtaggt 2520 attacttaag tgaatgttaa gagttccacc ctgagtggta atctaaggct gtgcagtcag 2580 ttacttcaga ctgctcagaa tagttcatta gaaaggtaac aaatgagaaa tgtattatta 2640 tacagttcta tagtagtgaa gtgatggaat acctttctta cttttgtgga gttacatctg 2700 atgctaagaa tttgacctcc aactaagcaa acattttaat gagcaaaagt tagtgttatt 2760 aaagtttttt tatgatagat ccaaattgag gacctgtgtc ctgttttat aagattgcaa 2820 cccagctatg ctcatttgtt tatgttttgt atatggctgc ttttgtgtta cagtggtaga 2880 gtttaggt taggacagag acctgcaaag caaaataatt tacagtctgg ccctttacag 2940 aaaagtttgc tgactcatgg tcaaaataaa tgaaaattttt ttgtgttagg gttgttaagc 3000 tagggttctt tttggtatca tatgcttatt tttgtaaat ctctcaataa aaaattattt 3060 3068 grams <210> 14 <211> 9710 <212> DNA <213> Artificial Sequence <400> 14 agttctcggg cgtacggcgc ggcctgtcct actgccgccg gcgccgcggc cgtcatgggg 60 ttcctgaaac tgattgagat tgagaacttt aagtcgtaca agggtcgaca gattatcgga 120 ccatttcaga ggttcaccgc catcattgga cccaatggct ctggtaagtc aaatctcatg 180 gatgccatca gctttgtgct aggtgaaaaa accagcacc tgcggtaa gaccctgcgg 240 gacctgatcc atggagctcc tgtgggcaag ccagctgcca accggcctt tgtcagcatg 300 gtctactctg aggaggtgc tgaggaccgt accttgccc gtgtcattgt aggaggttct 360 tctgagtaca agatchaaca caagtggtc caactacatg agtacagtga ggattagag 420 aagttgggca ttctcatca agctcgtaac ttcctcgttt tccagggtgc tgtggaatct 480 attgccatga agaaccccaa agagaggaca gctctatttg agagattag tcgttctggg 540 gagctggcgc aggagtatga caagcgaaag aaggaatgg tgaggctga agaggacaca 600 cagtttaattt accatcgcaa gaaaatatt gcggctgaac gcaaggaagc aaagcaggag 660 aaagaagagg ctgaccggta ccagcgcctg aaggatgagg tagtacggc tcaggtacag 720 ctgcagctct ttaagcttta ccataatgaa gtggaattg agaagctca caggaactg 780 gcctcaaga aaaggagat cgagaaggac aagaaagcgta tggaaggt ggaggatgaa 840 ctgaaggaga agaagga gctgggcaaa atgatgcggg agcagcagca gattgagaag 900 gagatcaagg agaaggactc agaattgaac cagaagcgg ctcagtacat caaagccaag 960 gagaacacct cccacaaaat caagaagctg gaagcagcca agaagtctct gcagaatgct 1020 1080 gtggagaagg ctcggcagga gtttgaaa cggatggaag aagagagtca gagtcagggc 1140 agagatttga cgttggagga gaatcaggtg aagaaatacc accggttgaa aagaagagcc 1200 agcaagagag cagctaccct ggcccaggag ctggagaaat tcaatcgaga ccagaaagct 1260 1320 caaaagctgc gggaaattga agaatcag aagcggattg agaaactgga ggaatacatc 1380 1440 gtggagatgg ccaagcggcg tattgaatgaa atcaataagg agctgaacca ggtgatggag 1500 cagctagggg atgcccgcat cgaccgccag gagagcagcc gccagcagcg aaaggcagag 1560 atatggaaa gcatcaagcg cctttaccct ggctctgtgt acggccgcct cattgaccta 1620 tgccagccca cacaaaagaa gtatcagatt gctgtaacca aggttttggg caagaacatg 1680 gatgccatta ttgtggactc ggagaagaca ggccgggact gtattcagta tatcaaggag 1740 cagcgtgggg agcctgagac cttcttgcct cttgactacc tggaggtgaa gcctacagat 1800 gagaaactcc gggagctgaa gggggccaag ctagtgattg atgtgattcg ctatgagcca 1860 cctcatatca aaaaggccct gcagtatgct tgtggcaatg cccttgtctg tgacaacgtg 1920 gaagatgccc gccgcattgc ctttggaggc caccagcgcc acaagacagt ggcactggat 1980 ggaaccctat tccagaagtc aggagtgatc tctggtgggg ccagtgacct gaaggccaag 2040 gcacggcgct gggatgagaa agcagtagac aagttgaaag agaagaagga gcgcttgaca 2100 gaggagctga aagagcagat gaaggcaaaa cggaaagagg cagagctgcg tcaggtgcag 2160 tctcaggccc atggactgca gatgcggctc aagtactccc agagtgacct agaacagacc 2220 aagacacgac atctagccct gaatctgcag gaaaaatcca agctggagag tgagctagcc 2280 aactttgggc ctcgcattaa tgatatcaag aggatcattc agagccgaga gagggaaatg 2340 aaagacttga aggagagat gaaccaggta gaggatgagg tgtttgaga gttttgtcgg 2400 gagattggtg tgcgcacat ccggtttt gaggagaaa aggtgaaacg gcagaatgaa 2460 atcgccaaga agcgtttgga gtttgagaat cagaagactc gcttgggcat tcagttggat 2520 tttgaaaaga accaactgaa ggaggaccaa gataagtac acatgtggga gcagacagtg 2580 aaaaaagatg aaaatgagat agaaaagctc aaaaagggg aaaaagaca catgaagatc 2640 atagatgaga ccatggctca gctacagac ctgaagaatc agcatctggc cagaagtcg 2700 gaagtgaatg acagaatca tgagatgag gagattcgta agaactcgg gggcgccaac 2760 aaggaaatga cccatttaca gaaggaggtg acagccattg agaccaagct tgaacagag 2820 cgcagtgacc gtcacaactt gctacaggcc tgtagatgc aggacattaa gttgccactg 2880 tcaaaaggca ccatggactga tattagtcag gagagggta gctcccaggg ggaggactca 2940 gtgagtggtt cacagagaat ttccagtatc tatgcacgag aggccctcat tgagattgac 3000 tacggtgatc tgtgtgagga tctgaaggat gcccaggctg aggaagagat caagcaagg 3060 atgaacacac tgcagcagaa gctgaatgag cagcagagtg tgcttcagcg tattgccgcc 3120 ccaacatga aggccatgga aaagctggaa agtgtccgag acaagttcca ggagacctca 3180 gatgagtttg aagcagcccg aaagcgagca aagaaggcca agcaggcatt cgaacagatc 3240 aagaaggagc gctttgaccg cttcaatgct tgttttgaat ctgtggctac caacattgat 3300 gagatctata aggccctgtc ccgcaatagc agtgcccagg cattcctggg ccctgagaac 3360 cctgaagagc cctacttgga tggcatcaac tacaactgtg tggctcctgg gaaacgcttc 3420 cggcctatgg acaacttgtc aggcggggag aagacagtgg cagctctggc cctgctcttt 3480 gccatccaca gctacaagcc agcccccttc ttcgtcctgg atgagattga tgctgccttg 3540 gataacacca acattggcaa ggtggcaaat tacatcaagg agcagtcgac ttgcaacttc 3600 caggccatcg tcatctctt caaggaggag ttctacacca aggccgagag cctcattgga 3660 gtctatcctg agcaagggga ctgtgtgatc agcaaagtcc tgaccttcga cctcaccaag 3720 tacccagatg ccaaccccaa ccccaatgag cagtagcagt atttttgccc tcccgccctg 3780 tctggatccc tagctgtcc ctctcccaat ctctggatat ttgactccca accttccccc 3840 tacctcctgg ccctttttgg tgtagtcatg ggatttaggc actgctaatc aagcatgaag aggaacagag gtgatgttag gtctggagca aaaattcctg aacgacaggg agtattctgg cctctgaaag gaggtgctga gctgaacagg gccatctgtt catcacacac acccccttcc tccccctcat cacccataat cgtgggcccc ttggggcctct tgcccactgt gtgtgtgggt 4080. atgtatgtgt gtatgtatgt atccgcatgt gtgcatgtga gtatgtttgc aaaataataa aggatattgg agacctgttt tagaaggagc ctaggctga tttgattcca agagagctta ggatgacagc acccctgagc tgggcaaagg tactcaggac ctcataggag tcttaggcag ttacctgaaa ctgccttcat tcactcattt gtgtattcat tcatttatgt attcatcaga cacataccga acaccctcta tttgtcaggc tctgtgcttg gaatacagag ttgaatcaga catgatctct accctcctag taggagata cagtgggttc atgaatgact atagttagct 4440 gaatgtcata tgtactttga atttgagaag tgggtgatcc cctctaggct tcctggaggt cacatttaag ctagaccttg acaaattggt aggatttggt caggcactag gagtggagca 4560 tgagctctgg ggacagacag tttgggttc tggtcccact tttatcact tactagttgt 4620 ttgaccttgg gcaagtcatt tgaccttctg tgcctcagtt tcctcatctg taaaatgggg 4680 ctaacaatat tacctacctc ataggattta atgatgtcaa gctcctcact ggaggcctta 4740 tccctcgtg gagcccacta ggtgccgacc cctcagaata taaccctcat gcctggaccc 4800 ctgagagctt ctgatcccag ctattaggga cagaagaagc ctccaaatct ggaaggtgct 4860 gaatgccctg ctgactggga aagtttcagg gcactgatgg ggtctacctg gtaagcggag 4920 ggcctgagga aacctgtagc ttcaatcatg tctggtaacc gggtgcctga gccccaatct 4980 gggttgtgag gaaatagggg agaggtatcc tgggccacat cccagcctaa cacctgtgag 5040 gttcatttta ggaactaacc tcattagcta taaggatcat gcagaggcag caaagccggg 5100 tgcgatgagc tcagccttta ctcattcaca tacaccatca cactttaatt ccaatctgta 5160 tattgcttt taaaagttaa gtccattcta attacccaaa tatgcatgaa ttcattctcc 5220 ttttgagaag ttagattgtt aaagatagtc tcattcagct accaaccact ccttgatcct 5280 tcccttctta gtggctgttg tttgttgtac ttccgtttag actttgtttt aatgcttgta 5340 cgtacatatg tgaactcatt ggaaatattg tgtgtttaat gcaaatgata tattgaattg 5400 tttagcaatt tgttttcttt gcttaacgat gttttgaga tctgtgcatg ttacttaatg 5460 tagctcaatc catcttctgt aattgctgta tagattgtca tcatatgatt accacatttt 5520 acttacgcat ttctttgtg atggacatta agactgtttt taggttttgc tattacaaaa 5580 tactacacag gagcatcact atgcctgtgt gaaagtatat gtatgaaagt ttacctaggg 5640 ttgattccta gaagtggaat tgcaaagtca taggatattt atatattggt ttttaataat 5700 acttccaaat tgccctcctg tactatttac tcagtatttt tcttgaggtt gatctgaggt 5760 ctaacattgt tatcctatat cattttcatc ccaagtagtg atatctgtga aatcacaggt 5820 ttgatgtgtg ctaattatgt attcttctaa tacatattaa aagacataac tatcaaaaca 5880 aaataaattt gtctgttttc aaccaaagaa gtcacgtacc actggtggta ctgtgtgcca 5940 taatttggca aatgctggcc tttatggacg agcacaattc gggggtcaga cctggttcaa attctagctg tagaaacttg tgcaagttac ttcacctctg agcctaagtt tccacatctg taaaaggaga taataacac ctaccttgca gtagtgaagc aaagagaaaa ttaaatatat atgaagcaat ttggctggca tctagatcat tcacagccct ttaaaggtca cctttgctgt tctccccact ttacagataa ggaaactgag gcccaaaaag gtttgaaccc aggtcttcca agtcattcaa gtgctttctc cactgtacag gtggttatca accttggctg cgcatcagaa tcgtttgtaa agctttttct ttttcctttt taaaaagtaa agcaatat acacaggtaa aaaaataaaa tagtacagaa gggcttata tgagaagcag cagttccctg cttgcacccc cacatccaaa ggatgtggag ctctttaaaa ataattgct ctggtcccac ctctggaat ctgattcagc cagcatggat fatheracccag fathercc cctacctcac aggataaaa ggattacatg agatgcctta ggctaaggcc ctggcacaca ggacacatg tgctacaaag gagctttggg gacttaagtc ctgaggatcc aggaggtgag gtgacttgtc caagattcca ctggtttagt ggcagagcct agacttccac tcggatctat ttagtgcttg cccctgctc 6720 tctcctgtcg tgcccacca cctcctggca tcaggggca accgttgtca aggctatgct 6780 cacgggaggc tgggcaccac agtgttcca agagcaagct ggatccgagt agatcccta 6840 gggcttgttg gaggaactag ttgactccc ttatactgtg gacgcagtag ccttgctgta 6900 gggagttgaa gagtactcca cacagtatc ttaagtttaa ctgggcactt ccctctggaa 6960 atcacagtgt tgtgcaccag gaacacaag atgagtcaa tctttatcct gcctttgagg 7020 agctcactgt ttagttgggg aaaccatttg taaaacagcc atttaccata cagtgtgatc 7080 aacactgaca ggagcacagg aaaaacatct agcttagtg aagattcaga ggaggcatcc 7140 tgtagtctag gtggtgatac ctgactgag tcttgaggga cgggtaggaa ttagccagtt 7200 gaggagtag aaggaatttc cagatattgg aacagtag catgagaca tgaggcaag 7260 aaacagcaaa aaatactg aagcatgaag attcctgggg tgggggaa gcagcaagaa 7320 aaggtagaga ggaaccagat tggaagggg tcgtaaatgc atggctacag aattcagatt 7380 tgttttgtag gabagtgtgg ttcccaact ggctgtatac cacaaacagg tacggcattc 7440 tgggccccgg ccctaaaac attcattag tctggggtga tgttgttttgc 7500 tttaaaggt taccacatga ctaggggtaca gccagatttg gaaaccatag cttgaaggca 7560 gtgagggagc catgaaatgg ttttatag ggggactcca gatcagatgt gaacttaacc 7620 tgtttctggc tggctagcca accagcatgg aaaacagatt aggttagatg ttcatgctgt 7680 atgtgcccgt gcctgtagct tccctgttaa tcagctctt acactact atttgcttat 7740 ttgtctctg ataagcttt aggcaccaca agggtgggcc tgggatatt ttgcttacca 7800 gtatagcccc tgcaaaaag cacagtgcct gatacaac agcacccg taaagttttt 7860 gatgaatga atgcatgagt gatccattt gtgagagagc gatgagat gaagatta 7920 gctaggagac tggaaaag ccaggaggcc tgcactaggg gctaggagg gctaggccag taggataga 7980 8040 atgtggaggg tgactgagag gatgaatga gtacccatga atgccatga ttcctaccct 8100 gtcccagtca tctctttcct tatccatctc tgaaacaatc tgcttacatc ctcctcagca 8160 actggaattc ctcaagttag ttagacattc tgtgtgctgt gtggtctctc actgcccccc 8220 cactccccac ccctccacaa gccattgatt cattcatcca gttcaataaa tcttggctaa 8280 gcacctccag tgtgcagtaa ggctcttcca agccaggact ctgactccct ctttcctacc 8340 tcaagagatg tttttgaggg ctttcccagg taagagtcac atctcttata caataactta 8400 tagtgagata cccagaatgt cagacttgta agggaagact gcccaaaccc cttctgaggt 8460 cctcagaggg gaattaactt cctaaggtcc gactgctagg aagtgttgga gccagaaatg 8520 gaagctaggt ttcctttcta tgtcatctct ggagtcttga tcttgatcta tcccattgta 8580 gatcaggaca ggcagaggtg gtcagggaga aggtgggact taggttgaac cttgaaggtc 8640 aatgtattgg acaggtcaaa caagatggtt gccaattaca ctgccccctt ctggaaaccc 8700 ttagcaaacc tgccatgctt gcagtccctt ctaaggggtt tccttagcat aagttgccat 8760 gctctgtacc atgtgacctc acaatcctgg ccacagatag ctagatgtgg atagtgtctg 8820 gttcaagggc aaccaatctc taggctggcc agtggctgt tagctggact ggcatagga 8880 cttcacctta caggggtggc atgtatcaa tggcaatgt atgaacac cagatctttc 8940 maximum atgtgagct attcaxaga maximum attagaatt maximum 9000 ttagtggtgg tggatgaggg gtggccagaa actaaacagc aaagcaag agaagctgc 9060 agaaaccata agtaagcaga ggtcatgaga cattgtata atgagatcac ggagccacag 9120 ggtggcagaa gccatgaagc agcaaggcaa caatgggcta gaagccatga agcaatagga 9180 gccacgagga acagaaccg tgagacaaaa ctgactatga gatccacaaa gcagcagaag 9240 gcttgaatag aatagatcat gagacagtag aagcgatgag actgchaagaa ccacaggta 9300 gccagaacca tgtggcaaca tggcacagg aatggaagg gcagcaggag ctacaatgca 9360 gaaaagccat ggattaatag gaactgaagc gccgggagcc atgaagctgc aggaccaccatg 9420 aggcagaaaa agccatgggc tagcatcgag gggggcagaa agaagttagt cagtagcagt 9480 aggaggagta taaatacagc cagaaggag ttgagtcacc aatttgggaa gcactagaga 9540 agggagcaac agatgcctgc agctgagggg gtgacaagat aagccaggct ctagagctgc 9600 tttggatcat gaaccatttt caagtttctg ttcttccatg aggctgcctg tgtagctgtt 9660 cttgtcttcc ttatttccct gtgaatgctt taataaatcc ccatcactaa 9710 <210> 15 <211> 23 <212> DNA <213> Artificial Sequence <400> 15 cgagagacag tataccccaa tgg 23 <210> 16 <211> 18 <212> DNA <213> Artificial Sequence <400> 16 tgcgtcctcc agggtgat 18 <210> 17 <211> 19 <212> DNA <213> Artificial Sequence <400> 17 atgctgatgg cgaggctaa 19 <210> 18 <211> 19 <212> DNA <213> Artificial Sequence <400> 18 cgtcaccctc gtgcatctt 19 <210> 19 <211> 25 <212> DNA <213> Artificial Sequence <400> 19 tcaccattct gaaaaccaac ataag 25 <210> 20 <211> 19 <212> DNA <213> Artificial Sequence <400> 20 ctttcccatg cctgagcaa 19 <210> 21 <211> 19 <212> DNA <213> Artificial Sequence <400> 21 gccaagggtg tcccacatt 19 <210> 22 <211> 22 <212> DNA <213> Artificial Sequence <400> 22 tccaaagatt cccatggtga tc 22 <210> 23 <211> 21 <212> DNA <213> Artificial Sequence <400> 23 aaatgaggtt gttgggttcg a 21 <210> 24 <211> 25 <212> DNA <213> Artificial Sequence <400> 24 tccttccttc agtttccctt atagg 25 <210> 25 <211> 20 <212> DNA <213> Artificial Sequence <400> 25 catcaaggag tgggcattca 20 <210> 26 <211> 22 <212> DNA <213> Artificial Sequence <400> 26 tgaccagttc accattcctc aa 22 <210> 27 <211> 18 <212> DNA <213> Artificial Sequence <400> 27 ccatgcagct ggctgaaa 18 <210> 28 <211> 22 <212> DNA <213> Artificial Sequence <400> 28 tcgctcgtat aagccaatgt tg 22 <210> 29 <211> 19 <212> DNA <213> Artificial Sequence <400> 29 ggtgcccatg acccagact 19 <210> 30 <211> 22 <212> DNA <213> Artificial Sequence <400> 30 tttgcatggt cctgattttt ga 22 <210> 31 <211> 18 <212> DNA <213> Artificial Sequence <400> 31 tggcacggtt gctcaaca 18 <210> 32 <211> 23 <212> DNA <213> Artificial Sequence <400> 32 tggacttgtg ggctaaagaa atg 23 <210> 33 <211> 24 <212> DNA <213> Artificial Sequence <400> 33 tgaaggaaag aaaacaaaga acca 24 <210> 34 <211> 26 <212> DNA <213> Artificial Sequence <400> 34 cgtcaacact aaaataaaag gcaaac 26 <210> 35 <211> 21 <212> DNA <213> Artificial Sequence <400> 35 gggaaatgaa cgtgagggaa t 21 <210> 36 <211> 22 <212> DNA <213> Artificial Sequence <400> 36 gaatttccac acaaacgtcc aa 22 <210> 37 <211> 26 <212> DNA <213> Artificial Sequence <400> 37 attaggtttt cttttgtttt tgttct 26 <210> 38 <211> 28 <212> DNA <213> Artificial Sequence <400> 38 tagacaatac gaaataaata taaagcag 28 <210> 39 <211> 21 <212> DNA <213> Artificial Sequence <400> 39 cccagctatg ctcatttgtt t 21 <210> 40 <211> 23 <212> DNA <213> Artificial Sequence <400> 40 taaattattt tgctttgcag gtc 23 <210> 41 <211> 23 <212> DNA <213> Artificial Sequence <400> 41 gttttctttg cttaacgatg ttt 23 <210> 42 <211> 22 <212> DNA <213> Artificial Sequence <400> 42 agaaatgcgt aagtaaaatg tg 22 <210> 43 <211> 16 <212> DNA <213> Artificial Sequence <400> 43 ccctgctgtt ccaaaa 16 <210> 44 <211> 14 <212> DNA <213> Artificial Sequence <400> 44 ctgggcctcc cacg 14 <210> 45 <211> 16 <212> DNA <213> Artificial Sequence <400> 45 cacaatggca cctacc 16 <210> 46 <211> 14 <212> DNA <213> Artificial Sequence <400> 46 ccaacaccgc cctc 14 <210> 47 <211> 20 <212> DNA <213> Artificial Sequence <400> 47 ctaatctgac atcactggtg 20 <210> 48 <211> 16 <212> DNA <213> Artificial Sequence <400> 48 tcctgagcaa cttgca 16 <210> 49 <211> 13 <212> DNA <213> Artificial Sequence <400> 49 ccccgagacg agc 13 <210> 50 <211> 19 <212> DNA <213> Artificial Sequence <400> 50 tgagaatatc accttggcc 19 <210> 51 <211> 20 <212> DNA <213> Artificial Sequence <400> 51 acctcggaca aattcaggaa 20 <210> 52 <211> 21 <212> DNA <213> Artificial Sequence <400> 52 taatcaagct ttgaaagtcc t 21 <210> 53 <211> 19 <212> DNA <213> Artificial Sequence <400> 53 cagcaaatct gatccaaca 19 <210> 54 <211> 30 <212> DNA <213> Artificial Sequence <400> 54 tggaaaaaca gaagactctt actgcctcat 30 <210> 55 <211> 30 <212> DNA <213> Artificial Sequence <400> 55 tgttttgtat atggctgctt ttgtgttaca 30 <210> 56 <211> 31 <212> DNA <213> Artificial Sequence <400> 56 tgagatctgt gcatgttact taatgtagct c 31 <210> 57 <211> 24 <212> DNA <213> Artificial Sequence <400> 57 accatgagaa gtatgacaac agcc 24 <210> 58 <211> 23 <212> DNA <213> Artificial Sequence <400> 58 cacgatacca aagttgtcat gga 23 <210> 59 <211> 23 <212> DNA <213> Artificial Sequence <400> 59 tcagcaatgc ctcctgcacc acc 23
Claims
1. An isolated nucleic acid molecule combination, which is a pulmonary nodule marker, comprising the following DNA sequences, or the corresponding mRNA sequences of the DNA sequences: a coding sequence of ZNF266 or its complementary sequence, a coding sequence of TNFSF10 or its complementary sequence, a coding sequence of MORF or its complementary sequence, a coding sequence of MCEMP1 or its complementary sequence, a coding sequence of TRAF5 or its complementary sequence, a coding sequence of SLC38A1 or its complementary sequence, and a coding sequence of HNRNPD or its complementary sequence, wherein: The coding sequence of ZNF266 is shown in SEQ ID NO:5, the coding sequence of TNFSF10 is shown in SEQ ID NO:6, the coding sequence of MORF is shown in SEQ ID NO:7, the coding sequence of MCEMP1 is shown in SEQ ID NO:8, the coding sequence of TRAF5 is shown in SEQ ID NO:9, the coding sequence of SLC38A1 is shown in SEQ ID NO:10, and the coding sequence of HNRNPD is shown in SEQ ID NO:
13.
2. The nucleic acid molecule combination according to claim 1, characterized in that The nucleic acid molecule combination also has a DNA sequence selected from one, any multiple or all of the following, or the corresponding mRNA sequence of the DNA sequence: a coding sequence of CEACAM4 or its complementary sequence, a coding sequence of S100A9 or its complementary sequence, a coding sequence of FCGR1A or its complementary sequence, a coding sequence of ROGDI or its complementary sequence, a coding sequence of TARBP1 or its complementary sequence, a coding sequence of SMA4 or its complementary sequence, and a coding sequence of SMC1A or its complementary sequence, wherein the coding sequence of CEACAM4 is shown in SEQ ID NO:1, the coding sequence of S100A9 is shown in SEQ ID NO:2, the coding sequence of FCGR1A is shown in SEQ ID NO:3, the coding sequence of ROGDI is shown in SEQ ID NO:4, the coding sequence of TARBP1 is shown in SEQ ID NO:11, the coding sequence of SMA4 is shown in SEQ ID NO:12, and the coding sequence of SMC1A or is shown in SEQ ID NO:
14.
3. The nucleic acid molecule combination according to claim 2, characterized in that: The nucleic acid molecule combination has a DNA sequence selected from any one of the following groups, or their corresponding mRNA sequences: a24: the coding sequence of FCGR1A or its complementary sequence, the coding sequence of ROGDI or its complementary sequence, the coding sequence of ZNF266 or its complementary sequence, the coding sequence of TNFSF10 or its complementary sequence, the coding sequence of MORF or its complementary sequence, the coding sequence of MCEMP1 or its complementary sequence, the coding sequence of TRAF5 or its complementary sequence, the coding sequence of SLC38A1 or its complementary sequence, the coding sequence of TARBP1 or its complementary sequence, the coding sequence of SMA4 or its complementary sequence, the coding sequence of HNRNPD or its complementary sequence and the coding sequence of SMC1A or its complementary sequence, a26: the coding sequence of CEACAM4 or its complementary sequence, the coding sequence of FCGR1A or its complementary sequence, the coding sequence of ROGDI or its complementary sequence, the coding sequence of ZNF266 or its complementary sequence, the coding sequence of TNFSF10 or its complementary sequence, the coding sequence of MORF or its complementary sequence, the coding sequence of MCEMP1 or its complementary sequence, the coding sequence of TRAF5 or its complementary sequence, the coding sequence of SLC38A1 or its complementary sequence, the coding sequence of TARBP1 or its complementary sequence, the coding sequence of SMA4 or its complementary sequence and the coding sequence of HNRNPD or its complementary sequence, a28: the coding sequence of CEACAM4 or its complementary sequence, the coding sequence of S100A9 or its complementary sequence, the coding sequence of FCGR1A or its complementary sequence, the coding sequence of ROGDI or its complementary sequence, the coding sequence of ZNF266 or its complementary sequence, the coding sequence of TNFSF10 or its complementary sequence, the coding sequence of MORF or its complementary sequence, the coding sequence of MCEMP1 or its complementary sequence, the coding sequence of TRAF5 or its complementary sequence, the coding sequence of SLC38A1 or its complementary sequence, the coding sequence of SMA4 or its complementary sequence, the coding sequence of HNRNPD or its complementary sequence and the coding sequence of SMC1A or its complementary sequence, a29: the coding sequence of CEACAM4 or its complement, the coding sequence of S100A9 or its complement, the coding sequence of FCGR1A or its complement, the coding sequence of ROGDI or its complement, the coding sequence of ZNF266 or its complement, the coding sequence of TNFSF10 or its complement, the coding sequence of MORF or its complement, the coding sequence of MCEMP1 or its complement, the coding sequence of TRAF5 or its complement, the coding sequence of SLC38A1 or its complement, the coding sequence of TARBP1 or its complement, the coding sequence of HNRNPD or its complement, and the coding sequence of SMC1A or its complement, or a30: the coding sequence of CEACAM4 or its complementary sequence, the coding sequence of S100A9 or its complementary sequence, the coding sequence of FCGR1A or its complementary sequence, the coding sequence of ROGDI or its complementary sequence, the coding sequence of ZNF266 or its complementary sequence, the coding sequence of TNFSF10 or its complementary sequence, the coding sequence of MORF or its complementary sequence, the coding sequence of MCEMP1 or its complementary sequence, the coding sequence of TRAF5 or its complementary sequence, the coding sequence of SLC38A1 or its complementary sequence, the coding sequence of TARBP1 or its complementary sequence, the coding sequence of SMA4 or its complementary sequence, the coding sequence of HNRNPD or its complementary sequence and the coding sequence of SMC1A or its complementary sequence.
4. A reagent for detecting the transcription level, translation level, or content of the nucleic acid molecule combination according to any one of claims 1 to 3 in a sample.
5. The reagent according to claim 4, characterized in that The reagents are selected from reagents used in one or more of the following methods: PCR, DNA sequencing, RNA sequencing, DNA hybridization, RNA hybridization, Southern, Northern, Western, immunoprecipitation, ELISA, restriction endonuclease analysis, high-resolution melting curve method, and mass spectrometry.
6. The reagent according to claim 4, characterized in that The reagents are selected from reagents used in one or more of the following methods: RT-qPCR or a chip-based method.
7. The reagent according to claim 4, characterized in that The reagents are reagents used in RNA sequencing.
8. The reagent according to claim 4, characterized in that The reagents further comprise one or more of the following: buffer, reverse transcriptase, polymerase, dNTP, primer, probe, restriction endonuclease, fluorescent dye, fluorescent quencher, fluorescent reporter, exonuclease, alkaline phosphatase, internal standard, and control.
9. A kit comprising the reagent according to any one of claims 4 to 8.
10. The kit according to claim 9, characterized in that The kit further comprises the nucleic acid molecule combination according to any one of claims 1 to 3.
11. The kit according to claim 9, characterized in that The kit also comprises primers and / or probes for detecting the reference sequence.
12. Use of a detection reagent for the DNA or RNA sequence of the following genes in the human genome in the preparation of a reagent or kit for distinguishing benign from malignant pulmonary nodules: ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1, and HNRNPD.
13. The use according to claim 12, characterized in that The genes also include one or more genes selected from the group consisting of: CEACAM4, S100A9, FCGR1A, ROGDI, TARBP1, SMA4 and SMC1A.
14. The use according to claim 12 or 13, characterized in that The reagent detects the transcription level, translation level, content or methylation of the gene in the sample.
15. The use according to claim 12 or 13, characterized in that The reagents are primers or probes.
16. The use according to claim 12 or 13, characterized in that Pulmonary nodules are tiny nodules in the lungs.
17. The use according to claim 12 or 13, characterized in that The gene is selected from any one of the following groups: a24: FCGR1A, MCEMP1, MORF, ROGDI, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD and SMC1A, a26: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4 and HNRNPD, a28: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD and SMC1A, a29: CEACAM4, FCGR1A, CEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, HNRNPD, and SMC1A or a30: CEACAM4, FCGR1A, MCEMP1, MORF, ROGDI, S100A9, SLC38A1, TARBP1, TNFSF10, TRAF5, ZNF266, SMA4, HNRNPD and SMC1A.
18. Use of the reagent according to any one of claims 4 to 8 in the preparation of a kit for distinguishing benign and malignant pulmonary nodules.
19. Use of the combination of the reagent according to any one of claims 4 to 8 and the nucleic acid molecule according to any one of claims 1 to 3 in the preparation of a kit for distinguishing benign from malignant pulmonary nodules.
20. The use according to claim 18 or 19, characterized in that The pulmonary nodules are micropulmonary nodules.
21. The use according to claim 18 or 19, characterized in that The kit is a real-time quantitative PCR kit or a kit containing a gene chip.
22. The use according to claim 18 or 19, characterized in that The kit is an RNA sequencing kit.
23. A device, characterized in that: The device comprises a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the following steps when executing the program: (1) Obtain the expression test results of the DNA or RNA sequences of the following genes in the sample in the human genome: ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1 and HNRNPD, (2) obtaining a score by constructing a model using the expression detection results, and (3) Differentiate between benign and malignant pulmonary nodules based on the score.
24. The device according to claim 23, characterized in that The genes also include one or more genes selected from the group consisting of: CEACAM4, S100A9, FCGR1A, ROGDI, TARBP1, SMA4 and SMC1A.
25. The device according to claim 23 or 24, characterized in that The pulmonary nodules are micropulmonary nodules.
26. A system for distinguishing benign and malignant pulmonary nodules, characterized in that: include: A collection device is used to obtain the expression detection results of the DNA or RNA sequences of the following genes in the human genome in the sample: ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1 and HNRNPD, A data processing device, used to obtain a score by constructing a model using the detection result, The determination device is used to distinguish benign or malignant pulmonary nodules based on the scores.
27. The system of claim 26, wherein: The genes also include one or more genes selected from the group consisting of: CEACAM4, S100A9, FCGR1A, ROGDI, TARBP1, SMA4, and SMC1A.
28. The system according to claim 26 or 27, characterized in that The pulmonary nodules are micropulmonary nodules.
29. A method for screening genes for distinguishing benign and malignant pulmonary nodules, comprising the steps of: (1) Obtain gene expression data of malignant pulmonary nodule samples and benign pulmonary nodule samples, (2) Select genes that are expressed in all samples for T-test analysis. (3) Compare the differences in gene expression between malignant and benign pulmonary nodule samples, and select genes with a statistical P value less than 0.05 and a gene expression change of more than 1.1 times as candidate genes. Optional (4) Sort by correlation between gene expression data and benign or malignant samples, select genes with high correlation with malignant pulmonary nodules as gene group I; select genes with high correlation with gene group I from the remaining genes as gene group II; then pair the genes in gene group I and gene group II in pairs to form a candidate gene combination, and (5) Use logistic regression statistical analysis to screen candidate genes. The genes for distinguishing benign and malignant pulmonary nodules include: ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1 and HNRNPD, and one or more genes selected from the group consisting of CEACAM4, S100A9, FCGR1A, ROGDI, TARBP1, SMA4 and SMC1A.
30. The method of claim 29, wherein: The pulmonary nodules are micropulmonary nodules.
31. A method for constructing a model for distinguishing benign and malignant pulmonary nodules, comprising the steps of: (1) Obtain the expression test results of the DNA or RNA sequences of the following genes in the sample in the human genome: ZNF266, TNFSF10, MORF, MCEMP1, TRAF5, SLC38A1 and HNRNPD, and (2) Calculate the ROC curve and area under the curve for each candidate gene combination, and establish a model using logistic regression statistical analysis method.
32. The method of claim 31, wherein: The genes also include one or more genes selected from the group consisting of: CEACAM4, S100A9, FCGR1A, ROGDI, TARBP1, SMA4, and SMC1A.
33. The method according to claim 31 or 32, characterized in that The pulmonary nodules are micropulmonary nodules.
